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1. 
SELF-ASSEMBLED MONOLAYERS AND 
METHODS FOR USING THE SAME IN 
BOSENSINGAPPLICATIONS 
GRANT SUPPORT 
This work was supported in part by the National Science 
Foundation (NSF Grant EPSCoR RII (2010-2015)). The 
Government may have certain rights in the invention, as 
specified by law. 
FIELD OF THE INVENTION 
The present invention relates to new self-assembled mono 
layers (SAMs) that are useful in the fabrication of biosensors. 
BACKGROUND OF THE INVENTION 
The present invention relates to biosensors that are capable 
of rapidly quantifying the concentration of biomolecules in a 
sample solution with high accuracy in a simplified manner, 
and to methods of producing same. 
The detection of a ligand by a receptor (for example, detec 
tion of a hormone, an antigen or a pathogenic agent) is impor 
tant in the diagnosis of diseases and finding of useful biomol 
ecules. Many rapid test methods for detecting ligands with 
high selectivity and sensitivity have been developed. These 
include radio-activity-based assays, chemiluminescence 
assays, magnetic based assays, and fluorescence or colori 
metric assays. Immunoassays, such as enzyme-linked immu 
nosorbent assay (ELISA), enzyme immunoassay (EIA), and 
radioimmunoassay (RIA), are also well known for the detec 
tion of ligands Such as hormones, antigens or antibodies. The 
basic principle in many of these assays is that a marker 
conjugated (for example, an enzyme-, chromogen-, fluoro 
gen-, or radionucleotide-conjugated) antibody permits anti 
gen detection upon antibody binding. In order for this 
interaction to be detected as a change in color, fluorescent or 
radioactive complexes, significant numbers of antibodies 
must be bound to a correspondingly large number of antigen 
epitopes. The resulting labeled binding complex often must 
be isolated from the labeled marker molecules for detection. 
Although the prior art methods for measuring biological 
analytes of interest are useful, many problems arise in the 
application of these methods in biosensor platforms, such as 
low sensitivity, selectivity and stability of the sensing device. 
Moreover, existing methods are often time intensive, tedious 
and costly. Accordingly, there remains a need for sensitive 
and robust screening methods for detecting biomolecules in a 
sample. 
Electrochemical biosensors such as an electrochemical 
peptide-based (E-PB) sensor offer a convenient way to con 
jugate biosensing elements labelled with a redox molecule on 
a gold-lectrode Surface. To date, the most straightforward 
method to fabricate an E-PB sensor involves direct adsorption 
of thiolated peptide probes onto the gold electrode surface. 
Despite being a valuable probe immobilization strategy, con 
ventional methods lacks general Surface modification versa 
tility. 
SUMMARY OF THE INVENTION 
Applicants have found that, Surprisingly, a more conve 
nient approach is to first assemble a self-assembled mono 
layer (SAM) containing terminal reactive groups that may 
serve as a platform onto which one can couple different 













bilization approach described herein offers a significant 
advantage of Versatility in sensor fabrication. 
The present invention provides compounds that form self 
assembled monolayers that are useful in the fabrication of 
biosensors. In particular, the present invention provides self 






R-V 2 Y-R 
wherein constituent members are provided herein below. 
The present invention further provides a method for detect 
ing one or more biomolecules in a sample which comprises 
the steps of (a) providing a component that comprises a self 
assembled monolayer comprising a compound of Formula I 
or II; (b) binding a multivalent cation to the monolayer; (c) 
capturing a binding partner onto the monolayer, wherein the 
binding partner comprises a detectable marker and a moiety 
capable of binding the multivalent cation; (d) exposing the 
sample to the monolayer component; and (e) detecting a 
signal of the detectable marker. 
The present invention further provides methods for detect 
ing any ligand for a binding partner, Such as, without limita 
tion, Small-molecules, hormones, proteins, peptides, nucleic 
acids, lipids, antigens or antibodies. 
The present invention further provides methods for detect 
ing specific ligands Such as anti-peanutantigen and anti-HIV 
p24 antibody. 
The present invention further provides a kit for detecting 
one or more target molecules in a sample. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic showing immobilization of a histi 
dine-tagged methylene blue (His-MB) construct onto an 
imidazole-nickel-bound self-assembled monolayer (SAM) 
of the invention. 
FIG. 2 depicts (A) alternating current Voltammograms 
(ACVs) of His-MB immobilized on an imidazole-Ni SAM 
before and after displacement by free imidazole; and (B) a 
representative displacement/replacement plot for a His-MB 
SAM. 
FIG.3 depicts ACVs of a His-MB peptide-bound SAM in 
the presence of varying concentrations of anti-peanut IgY. 
FIG. 4 depicts ACVs of (A) His-MB immobilized on an 
imidazole-Co SAM before and after displacement by free 
imidazole; and (B) His-MB immobilized on an imidazole 
Zn SAM before and after displacement by free imidazole. 
FIG. 5 depicts ACVs of (A) His-MB immobilized on an 
imidazole-Ni SAM before and after displacement by free 
histamine; and (B) His-MB immobilized on an imidazole-Ni 
SAM before and after displacement by free histidine. 
FIG. 6 depicts ACVs of (A) His-MB immobilized on a 
nitrolotriacetic acid-Ni SAM before and after displacement 
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by free imidazole; and (B) His-MB immobilized on a 1,4,7- 
triazacyclononane-Zn SAM before displacement by free imi 
dazole. 
FIG.7 depicts ACVs of a His-MB peptide-bound SAM in 
the absence and presence of anti-p24 antibodies. 
FIG. 8 depicts structures of three imidazole-containing 
molecules of the invention. 
FIG.9 depicts ACVs of His-MB immobilized on SAMs 
fabricated using compounds C11-Im, dS1-Im, and dS2-Im. 
FIG. 10 depicts ACVs of His-MB modified (A) dS1-Im 
and (B) dS2-Im SAMs before and after displacement by 
Ni(II), and after replacement by His-MB. 
DETAILED DESCRIPTION 
The instant invention provides, inter alia, self-assembled 
monolayers (SAMs) that can be used to immobilize binding 
partners such as peptides in the fabrication of electrochemical 
peptide-based sensors. 
Compounds 
In some embodiments, the present invention provides a 
self-assembled monolayer comprising a compound of For 
mula I or II: 
II 
R-U sas X-R 
sas 
R-V 21 Y-R 
wherein: 
a dashed line indicates an optional bond; 
R-R are each, independently, Coalkyl, SR, OH, 
COR, heterocyclyl, heteroaryl, alkenyl, alkynyl, CN, N, or 
halo; 
Rs and R are each, independently, absent, H, or R.; 
R is 0-2R groups. 
X, Y, U, and V are each, independently, Coalkyl, 
C2-20alkenyl, C2-20alkynyl, C-20alkyl ether, C2-20alkenyl 
ether, or Coalkynyl ether, 
R is H. Coalkyl, C(O)H, CO-(Coalkyl), SH, or 
S(C-2alkyl); 
R, is Co-ohydroxyl, Coheterocycloalkyl, Cs-oaryl, 
Coheteroaryl, or NR'R''. 
R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, 
hydroxyl, halo, haloalkyl, haloalkoxy, cyano, nitro, azido, 
amino, alkylamino, dialkylamino, carboxy, carboxyalkyl 
ester, carboxy aryl ester, aminocarbonyl, alkylaminocarbo 
nyl, dialkylaminocarbonyl, Sulfonyl, aminosulfonyl, alky 
laminosulfonyl, dialkylaminosulfonyl, arylsulfonyl, aryl 
sulfinyl, alkylsulfonyl, or arylsulfonyl; and 
R and R' are each, independently selected from H, sub 
stituted or unsubstituted alkyl, 
or R and R' come together to form a 4-10-membered 
substituted or unsubstituted heterocyclic ring. 
In some embodiments, at least one of R-R is SR. 
In some embodiments, at least one of R-R is S(C- 














In some embodiments, at least one of R-R is SH or 
SC(O)(Coalkyl). 
In some embodiments, at least one of R-R is SH. 
In some embodiments, at least one of R-R is SC(O) 
(C-20alkyl). 
In some embodiments, at least one of R-R is SC(O)CH. 
In some embodiments, R and R are SR. 
In some embodiments, RandR are S(Coalkyl), SC(O) 
(Coalkyl), SH, or S(Coalkyl). 
In some embodiments, R 
SC(O)(Coalkyl). 
In some embodiments R and R are SH. 
In some embodiments, R and R2 are SC(O)(Coalkyl). 
In some embodiments, R and R are SC(O)CH. 
In some embodiments, at least one of R-R is OH, C(O) 
R. N. heterocyclyl, or heteroaryl. 
In some embodiments, at least one of R-R is OH. 
In some embodiments, at least one of R-R is heterocyclyl 
or heteroaryl. 
In some embodiments, at least one of R-R is heterocy 
clyl. 
In some embodiments, at least one of R-R is 1.4.7-triaza 
cyclononanyl. 
In some embodiments, at least one of R-R is heteroaryl. 
In some embodiments, at least one of R-R is pyridyl or 
imidazolyl. 
In some embodiments, at least one of R-R is pyridyl. 
In some embodiments, at least one of R-R is imidazolyl. 
In some embodiments, at least one of R-R is azido. 
In some embodiments, at least one of R-R is CN. 
In some embodiments, R and ROH, C(O)R. N. hetero 
cyclyl, or heteroaryl. 
In some embodiments, R and Ra are OH. 
In some embodiments, R and R are heterocyclyl or het 
eroaryl. 
In some embodiments, R and Ra are heterocyclyl. 
In some embodiments, R and R are 1,4,7-triazacy 
clononanyl. 
In some embodiments, R and Ra are heteroaryl. 
In some embodiments, RandR are pyridyl or imidazolyl. 
In some embodiments, R and Ra are pyridyl. 
In some embodiments, R and Ra are imidazolyl. 
In some embodiments, R and Ra are azido. 
In some embodiments, R and Ra are CN. 
In some embodiments, at least one of X, Y, U, and V is 
C1-20alkyl. 
In some embodiments, at least one of X, Y, U, and V is 
Cisalkyl. 
In some embodiments, at least one of X, Y, U, and V is 
Coalkyl. 
In some embodiments, X, Y, U, and V are Coalkyl. 
In some embodiments, X, Y, U, and V are Cisalkyl. 
In some embodiments, X, Y, U, and V are C-alkyl. 
In some embodiments, at least one of X, Y, U, and V is 
C2-20alkynyl. 
In some embodiments, at least one of X, Y, U, and V is 
Calkynyl. 
In some embodiments, X, Y, U, and V are Coalkynyl. 
In some embodiments, X, Y, U, and V are Calkynyl. 
In some embodiments, Rs and R are absent. 
In some embodiments, R, is OR groups. 
In some embodiments, the compound is a compound of 
Formula I. 
In some embodiments, the compound is a compound of 
Formula II. 
In some embodiments, the compound is a compound of 
Formula I, wherein: 
and R are SH or 
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RandR are SR; 
R and Rare OH: 
X, Y, U, and V are each, independently, Coalkyl, and 
Rs and R are absent. 
In some embodiments, the compound is a compound of 5 
Formula I, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Rare OH: 
X, Y, U, and V are each, independently, Cisalkyl; and 
Rs and R are absent. 
In some embodiments, the compound is a compound of 
Formula I, wherein: 
R and R are SH or SCOCH: 
R and Rare OH: 
X and Y are Calkyl: 
U, and V are Calkyl; and 
Rs and R are absent. 
In some embodiments, the compound is a compound of 
Formula I, wherein: 
R and Rare SR; 
R and Ra are OH: 
X, Y, U, and V are each, independently, Coalkyl, and 
Rs and R are H. 
In some embodiments, the compound is a compound of 
Formula I, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Rare OH: 
X, Y, U, and V are each, independently, Cisalkyl; and 
Rs and R are H. 
In some embodiments, the compound is a compound of 
Formula I, wherein: 
R and Rare SH or SCOCH: 
R and Ra are OH: 
X and Y are Calkyl 
U, and V are Calkyl; and 
Rs and R are H. 
In some embodiments, the compound is a compound of 
Formula I, wherein: 
R and Rare SR; 
R and Ra are heteroaryl; 
X, Y, U, and V are each, independently, Coalkyl, and 
Rs and R are absent. 
In some embodiments, the compound is a compound of 
Formula I, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are heteroaryl; 
X, Y, U, and V are each, independently, Cisalkyl; and 
Rs and R are absent. 
In some embodiments, the compound is a compound of 50 
Formula I, wherein: 
R and R are SH or SCOCH: 
R and Ra are heteroaryl; 
X and Y are Calkyl 
U, and V are Calkyl; and 
Rs and R are absent. 
In some embodiments, the compound is a compound of 
Formula I, wherein: 
R and R are SH or SCOCH: 
R and Ra are imidazolyl, 
X and Y are Calkyl 
U, and V are Calkyl; and 
Rs and R are absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
RandR are SR; 












X, Y, U, and V are each, independently, Coalkyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are heteroaryl; 
X, Y, U, and V are each, independently, Coalkyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO Calkyl: 
R and Ra are imidazolyl; 
X, Y, U, and V are each, independently, Cisalkyl, and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO Calkyl: 
R and Ra are imidazolyl; 
X and Y are each Calkyl: 
U and V are each Calkyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are Coalkyl, 
X, Y, U, and V are each, independently, Coalkyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO Calkyl: 
R and Ra are Calkyl: 
X, Y, U, and V are each C alkyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO Calkyl; 
R and Ra are pyridyl; 
X and Y are each Calkynyl: 
U and V are each Calkynyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are OH: 
X, Y, U, and V are Calkyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and R are OH or N: 
X, Y, U, and V are Calkyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are N: 
X, Y, U, and V are Calkyl; and 
R, is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are N: 
X, Y, U, and V are Csalkyl; and 
R, is absent. 
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In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are OH or N: 
X, Y, U, and V are Csalkyl; and 
R is absent. 
In some embodiments, wherein the compound is a com 
pound of Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are imidazolyl, 
X, Y, U, and V are Calkyl; and 
R is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are imidazolyl: 
X, Y, U, and V are Calkyl; and 
R is absent. 
In some embodiments, the compound is a compound of 
Formula II, wherein: 
R and R are SH or SCO Calkyl: 
R and Ra are imidazolyl, 
X and Y are each Calkyl; 
U and V are each Calkyl; and 
R is absent. 
In some embodiments, at least one of R or R is C(O)R. 
In some embodiments, R, is NR'R''. 
In some embodiments, NR'R' is a triazacyclononane 
group. 
In some embodiments, the triazacyclononane group is Sub 
stituted with an alkylcarboxylate. 
In some embodiments, NR'R' is NH(Coalkyl). 
In some embodiments, the NH(Coalkyl) is substituted 
with a nitrilotriacetic acid. 
At various places in the present specification Substituents 
of compounds of the invention are disclosed in groups or in 
ranges. It is specifically intended that the invention include 
each and every individual subcombination of the members of 
Such groups and ranges. For example, the term "Ce alkyl is 
specifically intended to individually disclose methyl, ethyl, 
Calkyl, Calkyl, Csalkyl, and Calkyl. 
For compounds of the invention in which a variable 
appears more than once, each variable can be a different 
moiety selected from the Markush group defining the vari 
able. For example, where a structure is described having two 
R" groups that are simultaneously present on the same com 
pound; the two R groups can represent different moieties 
selected from the Markush group defined for R. It is further 
appreciated that certain features of the invention, which are, 
for clarity, described in the context of separate embodiments, 
can also be provided in combination in a single embodiment. 
Conversely, various features of the invention which are, for 
brevity, described in the context of a single embodiment, can 
also be provided separately or in any Suitable Subcombina 
tion. 
As used herein, the term “alkyl is meant to refer to a 
saturated hydrocarbon group which is straight-chained or 
branched. Example alkyl groups include methyl (Me), ethyl 
(Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-bu 
tyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neo 
pentyl), and the like. An alkyl group can, for example, contain 
from 1 to about 20, from 2 to about 20, from 1 to about 10, 
from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 
1 to about 3 carbon atoms. 
As used herein, “alkenyl refers to an alkyl group having 
one or more double carbon-carbon bonds. Example alkenyl 













As used herein, “alkynyl refers to an alkyl group having one 
or more triple carbon-carbon bonds. Example alkynyl groups 
include ethynyl, propynyl, and the like. As used herein, 
"haloalkyl refers to an alkyl group having one or more halo 
gen Substituents. Example haloalkyl groups include CF, 
CFs, CHF, CC1, CHCl, CC1s, and the like. An alkyl 
group in which all of the hydrogen atoms are replaced with 
halogen atoms can be referred to as “perhaloalkyl.” 
As used herein, “alkylene' or “alkylenyl refers to a bivalent 
alkyl group. An example alkylene group is methylene or 
ethylene. 
As used herein, “alkenylene' or “alkenylenyl refers to a 
bivalent alkenyl group. As used herein, 'carbocyclyl groups 
are Saturated (i.e., containing no double or triple bonds) or 
unsaturated (i.e., containing one or more double or triple 
bonds) cyclic hydrocarbon moieties. Carbocyclyl groups can 
be mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) or 
spirocyclic. Example carbocyclyl groups include cyclopro 
pyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclo 
pentenyl, 1.3-cyclopentadienyl, cyclohexenyl, norbornyl, 
norpinyl, norcamyl, adamantyl, phenyl, and the like. Car 
bocyclyl groups can be aromatic (e.g., “aryl') or non-aro 
matic (e.g., “cycloalkyl). In some embodiments, carbocyclyl 
groups can have from about 3 to about 30 carbonatoms, about 
3 to about 20, about 3 to about 10, or about 3 to about 7 carbon 
atOmS. 
As used herein, the term “alkyl ether refers to an alkyl 
group or a cycloalkyl group as defined herein, having at least 
one oxygen incorporated into the alkyl chain e.g., methyl 
ethyl ether, diethyl ether, tetrahydrofuran. In some embodi 
ments alkyl ether groups can have from 1-20 carbonatoms. In 
some embodiments, the alkyl ether is a Copolyether group. 
As used herein, the term “alkenyl ether refers to an alkenyl 
group or a cycloalkenyl group as defined herein, having at 
least one oxygen incorporated into the alkene chain. In some 
embodiments alkenylether groups can have from 1-20 carbon 
atOmS. 
As used herein, the term “alkynyl ether refers to an alky 
nyl group or a cycloalkynyl group as defined herein, having at 
least one oxygen incorporated into the alkyne chain. In some 
embodiments alkynyl ether groups can have from 1-20 car 
bon atoms. 
As used herein, “aryl' refers to an aromatic carbocyclyl 
group including monocyclic or polycyclic (e.g., having 2, 3 or 
4 fused rings) aromatic hydrocarbons such as, for example, 
phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, inde 
nyl, and the like. In some embodiments, aryl groups have 
from 6 to about 20 carbon atoms. 
As used herein, "cycloalkyl refers to non-aromatic car 
bocyclyl groups including cyclized alkyl, alkenyl, and alky 
nyl groups. Cycloalkyl groups can include bi- or polycyclic 
(e.g., having 2, 3 or 4 fused rings) ring systems as well as spiro 
ring systems. Example cycloalkyl groups include cyclopro 
pyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclo 
pentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, 
norbornyl, norpinyl, norcarnyl, adamantyl, and the like. Also 
included in the definition of cycloalkyl are moieties that have 
one or more aromatic rings fused (i.e., having a bond in 
common with) to the cycloalkyl ring, for example, benzo 
derivatives of pentane, pentene, hexane, and the like. 
As used herein, "heterocyclyl or "heterocycle” refers to a 
saturated or unsaturated carbocyclyl group wherein one or 
more of the ring-forming carbon atoms of the carbocyclyl 
group is replaced by a heteroatom such as O, S, or N. Hetero 
cyclyl groups can be aromatic (e.g., "heteroaryl') or non 
aromatic (e.g., "heterocycloalkyl). Heterocyclyl groups can 
also correspond to hydrogenated and partially hydrogenated 
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heteroaryl groups. Heterocyclyl groups can be characterized 
as having 3-14 ring-forming atoms. In some embodiments, 
heterocyclyl groups can contain, in addition to at least one 
heteroatom, from about 1 to about 20, about 2 to about 10, or 
about 2 to about 7 carbon atoms and can be attached through 
a carbon atom or heteroatom. In further embodiments, the 
heteroatom can be oxidized (e.g., have an OXO or Sulfindo 
Substituent) or a nitrogenatom can be quaternized. Examples 
of heterocyclyl groups include morpholino, thiomorpholino, 
piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihy 
drobenzofuryl, 1,3-benzodioxole, benzo-1,4-dioxane, pip 
eridinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyra 
Zolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the 
like, as well as any of the groups listed below for "heteroaryl 
and "heterocycloalkyl.” Further example heterocycles 
include pyrimidinyl, phenanthridinyl, phenanthrolinyl, 
phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, 
phthalazinyl, piperazinyl, piperidinyl. 3,6-dihydropyridyl, 
1.2.3,6-tetrahydropyridyl, 1,2,5,6-tetrahydropyridyl, piperi 
donyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl. 
pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl pyridazinyl, 
pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, 
pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, 
pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahy 
droquinolinyl, tetrazolyl, 6H-1,2,5-thia-diazinyl, 1,2,3-thia 
diazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadia 
Zolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, 
thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1.2, 
3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, 
Xanthenyl, octahydro-isoquinolinyl, oxadiazolyl, 1.2.3-oxa 
diazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadia 
Zolyl, oxazolidinyl, oxazolyl, oxazolidinyl, quinazolinyl, 
quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, 
acridinyl, azocinyl, benzimidazolyl, benzofuranyl, ben 
Zothiofuranyl, benzo-thiophenyl, benzoxazolyl, benzthiaz 
olyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, ben 
Zisothiazolyl, benzimidazolinyl, methylenedioxyphenyl, 
morpholinyl, naphthyridinyl, deca-hydroquinolinyl, 2H.6H 
1.5.2dithiazinyl, dihydrofuro2.3-btetrahydrofuran, furanyl, 
furazanyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chroma 
nyl, chromenyl, cinnolinyl, imidazolidinyl, imidazolinyl, 
imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, 
indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isolinda 
Zolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyland 
isoxazolyl. Further examples of heterocycles include azeti 
din-1-yl, 2,5-dihydro-1H-pyrrol-1-yl, piperindin-1yl, piper 
azin-1-yl, pyrrolidin-1-yl, isoquinol-2-yl, pyridin-1-yl, 3.6- 
dihydropyridin-1-yl, 2,3-dihydroindol-1-yl, 13,49 
tetrahydrocarbolin -2-yl, thieno2.3-cpyridin-6-y1, 3,4,10. 
10a-tetrahydro-1H-pyrazino 1,2-alindol-2-yl, 1.2.4.4a.5,6- 
hexahydro-pyrazino 1,2-aquinolin-3-yl pyrazino 1.2-a 
quinolin-3-yl, diazepan-1-yl, 1,4,5,6-tetrahydro-2H-benzo 
fisoquinolin-3-yl, 1.4.4a.5,6,10b-hexahydro-2H-benzof 
isoquinolin-3-yl, 3.3a,8.8a-tetrahydro-1H-2-aza-cyclopenta 
alinden-2-yl, and 2.3.4.7-tetrahydro-1H -azepin-1-yl, 
aZepan-1-yl. Also included are fused ring and spiro com 
pounds containing, for example, the above heterocycles. 
As used herein, "heteroaryl groups are aromatic hetero 
cyclyl groups and include monocyclic and polycyclic (e.g., 
having 2, 3 or 4 fused rings) aromatic hydrocarbons that have 
at least one heteroatom ring member Such as Sulfur, oxygen, 
or nitrogen. Heteroaryl groups include, without limitation, 
pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, 
quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, 
pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, 
isoxazolyl pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4- 













benzimidazolyl, indolinyl, and the like. In some embodi 
ments, the heteroaryl group has from 1 to about 20 carbon 
atoms, and in further embodiments from about 3 to about 20 
carbon atoms. In some embodiments, the heteroaryl group 
contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming 
atoms. In some embodiments, the heteroaryl group has 1 to 
about 4, 1 to about 3, or 1 to 2 heteroatoms. 
As used herein, "heterocycloalkyl refers to non-aromatic 
heterocyclyl groups including cyclized alkyl, alkenyl, and 
alkynyl groups where one or more of the ring-forming carbon 
atoms is replaced by a heteroatom such as an O, N, or Satom. 
Example heterocycloalkyl groups include morpholino, thio 
morpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothie 
nyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo-1,4-di 
OXane, piperidinyl, pyrrolidinyl, isoxazolidinyl, 
isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, 
imidazolidinyl, and the like. Also included in the definition of 
heterocycloalkyl are moieties that have one or more aromatic 
rings fused (i.e., having a bond in common with) to the non 
aromatic heterocyclic ring, for example phthalimidyl, naph 
thalimidyl, and benzo derivatives of heterocycles such as 
indolene and isoindolene groups. In some embodiments, the 
heterocycloalkyl group has from 1 to about 20 carbon atoms, 
and in further embodiments from about 3 to about 20 carbon 
atoms. In some embodiments, the heterocycloalkyl group 
contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming 
atoms. In some embodiments, the heterocycloalkyl group has 
1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some 
embodiments, the heterocycloalkyl group contains 0 to 3 
double bonds. In some embodiments, the heterocycloalkyl 
group contains 0 to 2 triple bonds. 
As used herein, "halo” or “halogen' includes fluoro, 
chloro, bromo, and iodo. As used herein, “alkoxy' refers to an 
—O-alkyl group. Example alkoxy groups include methoxy, 
ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, 
and the like. As used herein, “aryloxy' refers to an —O-aryl 
group. An example aryloxy group is phenoxy. As used here, 
"haloalkoxy' refers to an —O-haloalkyl group. An example 
haloalkoxy group is OCF3. As used herein, “carbocyclyla 
lkyl refers to an alkyl moiety substituted by a carbocyclyl 
group. 
Example carbocyclylalkyl groups include “aralkyl (alkyl 
substituted by aryl (“arylalkyl)) and “cycloalkylalkyl (alkyl 
Substituted by cycloalkyl). In some embodiments, carbocy 
clylalkyl groups have from 4 to 24 carbon atoms. 
As used herein, "heterocyclylalkyl refers to an alkyl moi 
ety substituted by a heterocarbocyclyl group. Example het 
erocarbocyclylalkyl groups include “heteroarylalkyl (alkyl 
substituted by heteroaryl) and "heterocycloalkylalkyl (alkyl 
substituted by heterocycloalkyl). In some embodiments, het 
erocyclylalkyl groups have from 3 to 24 carbon atoms in 
addition to at least one ring-forming heteroatom. 
As used herein, “amino” refers to an NH group. “Alky 
lamino” refers to an amino group Substituted by an alkyl 
group and “dialkylamino” refers to an amino group Substi 
tuted by two alkyl groups. 
As used herein, “aminocarbonyl refers to CONH2. 
As used herein, “alkylaminocarbonyl refers to CONH 
(alkyl). 
As used herein, “alkylaminocarbonyl refers to CON 
(alkyl). 
As used herein, “carboxy” or “carboxyl refers to COOH. 
As used herein, "carboxyalkyl ester” refers to COO-alkyl. 
As used herein, “carboxyaryl ester” refers to COO-aryl. 
As used herein, “hydroxy' refers to OH. 
As used herein, “mercapto' refers to SH. 
As used herein, “sulfinyl refers to SO. 
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As used herein, “sulfonyl refers to SO. 
As used herein, “aminosulfonyl refers to SONH2. 
As used herein, “alkylaminosulfonyl refers to SONH 
(alkyl). 
As used herein, “dialkylaminosulfonyl refers to SON 
(alkyl). 
As used herein, “arylsulfonyl refers to SO-aryl. 
As used herein, “arylsulfinyl refers to SO-aryl. 
As used herein, “alkylsulfonyl” refers to SO-alkyl. 
As used herein, “alkylsulfinyl refers to SO-alkyl. 
Unless otherwise indicated, the compounds provided in the 
above formula are meant to include salts, enantiomers, dias 
tereomers, racemic mixtures, crystalline forms, non-crystal 
line forms, amorphous forms, hydrates and Solvates thereof. 
When compounds of the present invention contain rela 
tively basic functionalities, acid addition salts can be obtained 
by contacting the neutral form of Such compounds with a 
sufficient amount of the desired acid, either neat or in a 
suitable inert solvent. Examples of acceptable acid addition 
salts include those derived from inorganic acids like hydro 
chloric, hydrobromic, nitric, carbonic, phosphoric, partially 
neutralized phosphoric acids, Sulfuric, partially neutralized 
Sulfuric, hydroiodic, or phosphorous acids and the like, as 
well as the salts derived from organic acids like acetic, pro 
pionic, isobutyric, maleic, malonic, benzoic, succinic, 
Suberic, fumaric, mandelic, phthalic, benzenesulfonic, 
p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. 
Also included are salts of amino acids such as arginate and the 
like, and salts of organic acids like glucuronic or galactunoric 
acids and the like. Certain specific compounds of the present 
invention may contain both basic and acidic functionalities 
that allow the compounds to be converted into either base or 
acid addition salts. The neutral forms of the compounds of the 
present invention may be regenerated by contacting the salt 
with a base or acid and isolating the parent compound in the 
conventional manner. The parent form of the compound dif 
fers from the various salt forms in certain physical properties, 
such as solubility in polar solvents, but otherwise the salts are 
equivalent to the parent form of the compound for the pur 
poses of the present invention. 
As noted above, some of the compounds of the present 
invention possess chiral or asymmetric carbonatoms (optical 
centers) or double bonds; the racemates, diastereomers, geo 
metric isomers and individual optical isomers are all intended 
to be encompassed within the scope of the present invention. 
Compounds of the invention can also include all isotopes 
of atoms occurring in the intermediates or final compounds. 
Isotopes include those atoms having the same atomic number 
but different mass numbers. For example, isotopes of hydro 
gen include tritium and deuterium. 
Compounds of the invention can also include tautomeric 
forms, such as keto-enol tautomers. Tautomeric forms can be 
in equilibrium or sterically locked into one form by appropri 
ate Substitution. 
Some of the compounds of the invention can exist in unsol 
vated forms as well as Solvated forms, including hydrated 
forms. In general, the Solvated forms are equivalent to unsol 
vated forms and are intended to be encompassed within the 
Scope of the present invention. Certain compounds of the 
present invention may exist in multiple crystalline or amor 
phous forms. In general, all physical forms are equivalent for 
the uses contemplated by the present invention and are 




















































































In some embodiments of the invention, the compounds of 










As noted above, some of the compounds of the present 
invention possess chiral or asymmetric carbonatoms (optical 
centers) or double bonds; the racemates, diastereomers, geo 
metric isomers and individual optical isomers are all intended 
to be encompassed within the scope of the present invention. 
The compounds of Formula I and II have unique structural 
features that are useful for several applications. In particular, 
the inventive compounds contain two amphiphile chains that 
are joined by a non-polar linker comprising a carbon-carbon 
single, double or arene bond. This allows for highly organized 
and uniform binding of the amphiphile chains to a Surface for 
the formation of self-ssembled monolayers. The compounds 
of Formula I and II are believed to provide enhanced stability 
in monolayer structures compared to single-chain 
amphiphiles due to cooperative multivalent bonding of two 
amphiphile chains. The inventive compounds are also 
believed to adsorb onto metal surfaces at an enhanced rate 
with high packing density fostered by the cross-linking 
present in the structures. Upon packing into a monolayer or 
similar aggregate, the two chains of the cross-linked 
amphiphile are in close proximity. Varying the functionality 
on each chain allows construction of functionalized surfaces 
with an exceptional degree of lateral control. 
It has been discovered by Applicants that the structural and 
functional properties of the monolayer can be modulated by 
adjusting the linker groups and amphiphile chains of selected 
amphiphile compounds. For example, the rigidity of the 
monolayers can be controlled by changing the linker moiety 
(carbon-carbon single, double or arene bond-linker) and by 
adjusting the relative position of the crosslinker along the 
amphiphile chain. A vast array of functional groups may be 
appended at any point along the amphiphile chain to achieve 
absolute and independent control over the functionality on 
each segment. The cross-linking of the two amphiphile chains 
can be conducted at any location along the amphiphile to 
fine-tune the flexibility or rigidity at either end of the mol 
ecule. 
Synthesis 
The novel compounds of the present invention can be pre 
pared in a variety of ways known to one skilled in the art of 
organic synthesis. The compounds of the present invention 
can be synthesized using the methods as hereinafter described 
below, together with synthetic methods known in the art of 
synthetic organic chemistry or variations thereon as appreci 
ated by those skilled in the art. 
The compounds of this invention can be prepared from 
readily available starting materials using the following gen 
eral methods and procedures. It will be appreciated that where 
typical or preferred process conditions (i.e., reaction tem 
peratures, times, mole ratios of reactants, solvents, pressures, 
etc.) are given, other process conditions can also be used 
unless otherwise stated. Opimum reaction conditions may 













conditions can be determined by one skilled in the art by 
routine optimization procedures. 
The processes described herein can be monitored accord 
ing to any Suitable method known in the art. For example, 
product formation can be monitored by spectroscopic means, 
such as nuclear magnetic resonance spectroscopy (e.g., "Hor 
'C), infrared spectroscopy, spectrophotometry (e.g., UV 
visible), or mass spectrometry, or by chromatography Such as 
high performance liquid chromatograpy (HPLC) or thin layer 
chromatography. 
Preparation of compounds can involve the protection and 
deprotection of various chemical groups. The need for pro 
tection and deprotection, and the selection of appropriate 
protecting groups can be readily determined by one skilled in 
the art. The chemistry of protecting groups can be found, for 
example, in Green, et al., Protective Groups in Organic Syn 
thesis, 2d. Ed., Wiley & Sons, 1991, which is incorporated 
herein by reference in its entirety. 
The reactions of the processes described herein can be 
carried out in suitable solvents which can be readily selected 
by one of skill in the art of organic synthesis. Suitable solvents 
can be substantially nonreactive with the starting materials 
(reactants), the intermediates, or products at the temperatures 
at which the reactions are carried out, i.e., temperatures which 
can range from the solvents freezing temperature to the 
Solvents boiling temperature. A given reaction can be carried 
out in one solvent or a mixture of more than one solvent. 
Depending on the particular reaction step, Suitable solvents 
for a particular reaction step can be selected. 
The novel compounds of this invention may be prepared 
using the reaction pathways and techniques as described 
below. 
A series of compounds of formula 12 are prepared by the 
methods outlined in scheme 1 (where n of formulas 5-12 and 
m of formulas 7-12 correspond to appropriate values that 
would afford compounds of the invention). 1,2-dimethoxy 
benzene is treated with HIO and I in methanol to afford 
compound 2, which is reacted BBr to provide 3. The diol is 
then treated with Tf.C) in pyridine to provide the correspond 
ing triflate, which is alkylated with 5 to form product 6. 
Alkylation of 6 is accomplished by treating with compound 7 
to provide product 8. The alkyne and benzyl groups of 8 are 
removed by hydrogenation to provide compound 9. The 
resulting diol is treated with MsCl to form 10, which is then 
thiylated upon treatment with potassium thioacetate to afford 
product 11. The acetyl groups are removed with DIBAL-H to 
produce the final compound 12. 
Scheme 1 
MeO MeO I 
HSIO6. I2 BBr3 
He- He 
MeOH CHCl2 
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A series of compounds of formula 17 are prepared by the 
methods outlined in scheme 2 (where m of formulas 13-17 
corresponds to appropriate values that would afford com 
pounds of the invention). An alkeneol 13 is treated with PPh 
and N-chlorosuccinimide in THF to afford chloride 14, which 
undergoes cross-metathesis in the presence of Grubbs 2" 
generation catalyst and methylacrylate to provide 15. The 
enoate is then reductively dimerized in the presence of SmI 
to form product 16 as a mixture of stereoisomers. Displace 
ment of the chlorides with KSAc and global reduction with 
DIBAl-Haffords the final compound 17. 
Scheme 2 
PPh3 Methylacrylate 
NCS Grubbs 2 cat. 
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A series of compounds of formula 24 are prepared by the 
methods outlined in scheme 3 (where m of formulas 18-24 
corresponds to appropriate values that would afford com 
pounds of the invention). An alkynol is protected as the THP 
ether followed by lithiation and homologation of the terminal 
alkyne with methyl chloroformate to afford compound 19. 
Conjugate addition of an in situ prepared Stannylcuprate to 
the enoate affords vinyl Stannane compound 20, which under 
goes Cu(I)-mediated homocoupling to give bis enoate com 
pound 21. Reductive deconjugation under dissolving metal 
conditions affords compound 22 as a mixture of isomers. 
Removal of the THP protecting groups and activation as the 
methanesulfonate gives compound 23. Displacement of the 
sulfonate groups with KSAc and global reduction with 
DIBAl-H provides the final compound 24. 
Scheme 3 
1) DPH, PPTS 
-e- 
2) BuLi, CICOMe HO(HC)- E 
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The compounds described herein are ideally suited for 
several applications, including biomaterial fabrication, cor 
rosion resistance, lithographic patterning and microelectron 
ics fabrication. This new class of compounds can also be used 
to create highly stable self-assembled monolayers (SAMs) on 
metal and semiconductor Surfaces which can be used to fab 
ricate electrochemical biosensors. 
The term “self-assembled monolayer” (SAM), as used 
herein, refers to a relatively ordered assembly of molecules 
(including compounds of Formula I or II) adsorbed on a 
Surface, in which the molecules are oriented approximately 
parallel to each other and roughly perpendicular to the Sur 
face. Each of the molecules preferably includes a functional 
group that adheres to the Surface, and a portion that interacts 
with neighboring molecules in the monolayer to form the 
relatively ordered array. Preferably, all of the species that 
participate in the SAM include a functionality that binds, 
optionally covalently, to the surface, such as a thiol which will 
bind covalently to a metal. Such as gold, Surface. A self 
assembled monolayer on a Surface, in accordance with the 
invention, can be composed of a mixture of species (e.g. thiol 
species when gold is the Surface) that can present (expose) 
essentially any chemical or biological functionality. For 
example, they can include species terminating in a binding 
partner of an affinity tag, e.g. terminating in a chelate that can 
coordinate a metal Such as nitrilotriacetic acid which, when in 
complex with nickel atoms, captures a metal binding tagged 
species such as a histidine-tagged binding species. 
In some embodiments of the invention, the self-assembled 
monolayers can be used in a sensor to detect biomolecules in 
a sample. For example, in one embodiment, one or more 
biomolecules in a sample, can be detected by (a) providing a 
component that comprises a self-assembled monolayer com 
prising a compound of Formula I or II; (b) binding a multi 
Valent cation to the monolayer; (c) capturing a binding partner 
onto the monolayer, wherein the binding partner comprises a 
detectable marker and a moiety capable of binding the mul 
tivalent cation; (d) exposing the sample to the monolayer 














As used herein, the word "comprise or variations such as 
“comprises” or “comprising,” will be understood to imply the 
inclusion of a stated element or group of elements, but not to 
the exclusion of any other element or group of elements. 
As used herein, a “biomolecule' is any molecule of a type 
typically foundina biological system, whether Such molecule 
is naturally occurring or the result of Some external distur 
bance of the system (e.g., a disease, poisoning, genetic 
manipulation, etc.), as well as synthetic analogs and deriva 
tives thereof. Non-limiting examples of biomolecules include 
amino acids (naturally occurring or synthetic), peptides, 
polypeptides, glycosylated and unglycosylated proteins (e.g., 
polyclonal and monoclonal antibodies, receptors, interferons, 
enzymes, etc.), nucleosides, nucleotides, oligonucleotides 
(e.g., DNA, RNA, PNA oligos), polynucleotides (e.g., DNA, 
cDNA, RNA, etc.), carbohydrates, hormones, haptens, ste 
roids, toxins, etc. Biomolecules may be isolated from natural 
Sources, or they may be synthetic. 
In some embodiments, the self-assembled monolayer of 
the invention is composed of a plurality of compounds of 
Formula I or II, whereby a portion of the compounds are 
functionalized with a moiety that is capable of binding a 
multivalent cation. In some embodiments, at least about 5% 
of the compounds are functionalized with a moiety that is 
capable of binding a monovalent cation. In other embodi 
ments, at least about 1-5% or about 5-10% or about 20, 30,35, 
40, 45, or 50% of the compounds are functionalized with a 
moiety that is capable of binding a monovalent cation. 
In some embodiments, the SAM-functionalized moiety 
capable of binding a multivalent cation is a chelating mol 
ecule. By the term “chelating molecule' or “chelating agent' 
is meant a compound that has the ability to bond to a metalion 
through two or more atoms of the chelating agent to form a 
complex or a reaction product. The bonds may be covalent or 
ionic or a combination thereof. Examples of suitable chelat 
ing agents include acidic materials such as ethylenediamine 
tetraacetic acid, nitrilo triacetic acid and Sodium tripolyphos 
phate. Other Suitable chelating agents of the invention 
include, but are not limited to, chelating agents comprising 
nitrilotriacetic acid (NT A), 1,4,7-triazacyclononane 
(TACN), diethylene triamine pentaacetic acid (DTPA), 14.7, 
10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 
or imidazole moieties. Other Suitable chelating agents 
include, but are not limited to N,N'-di-L-histidylethane-1,2- 
diamine (Dhen), iminodiacetic acid (IDA), tris(carboxymeth 
yl)ethylenediamine (TED) carboxymethylated aspartic acid 
(CM-Asp), dipicolylamine (DPA), aminohydroxamine acid, 
salicylaldehyde, or ortho-phosphoserine (OPS). 
In some embodiments of the invention, a multivalent cation 
is attached to the monolayer upon binding to the SAM-func 
tionalized moiety, described above, that is capable of binding 
a multivalent cation. As used herein, the term “multivalent 
cation.” refers to materials capable of carryingapositive ionic 
charge of +2 or greater. In some embodiments, the multivalent 
cation is a divalent or trivalent cation. Nonlimiting examples 
of "multivalent cationic' materials include alkaline earth 
metal ions, aluminum ions and heavy metal ions. In some 
embodiments of the invention, the multivalent cation is 
nickel, cobalt, or zinc. In some embodiments, the multivalent 
cation is Zn(II), Co(II)), or Ni(II). In other embodiments of 
the invention, the multivalent cation is Fe(III), Cu(II), V(III), 
W(IV), Ca(II), Al(III) or Yb(III). 
In some embodiments of the invention, a binding partner is 
captured onto the monolayer, the binding partner comprising 
a detectable marker and a moiety capable of binding a mul 
tivalent cation. As used herein, term “binding or “bound 
refers to the interaction between a corresponding pair of 
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molecules that exhibit mutual affinity or binding capacity, 
typically specific or non-specific binding or interaction, 
including biochemical, physiological, and/or pharmaceutical 
interactions. Biological binding defines a type of interaction 
that occurs between pairs of molecules including proteins, 
nucleic acids, glycoproteins, carbohydrates, hormones and 
the like. Specific examples include antibody/antigen, anti 
body/hapten, enzyme? substrate, enzyme/inhibitor, enzyme? 
cofactor, binding protein/substrate, carrier protein/substrate, 
lectin/carbohydrate, receptor/hormone, receptor/effector, 
complementary strands of nucleic acid, protein/nucleic acid 
repressor/inducer, ligand/cell Surface receptor, virus/ligand, 
etc. 
Accordingly, as used, herein, a “binding partner” refers to 
a molecule that can undergo the aforementioned binding with 
a particular molecule. Biological binding partners are 
examples. For example, the protein Arah2 (or a peptide 
epitope therefrom) is a binding partner of anti-peanut anti 
body IgY, and vica versa. Accordingly, in Some embodiments 
of the invention, the binding partner is a biological binding 
partner. Suitable binding partners include, for example, pep 
tides, proteins, nucleic acids, glycoproteins, lipids, carbohy 
drates, hormones and the like. In some embodiments of the 
invention, the binding partner is a peptide, protein or nucleic 
acid. In one embodiment, the binding partner is a peptide. 
As used herein, a "peptide' is an oligomer in which the 
monomers are amino acids and which is joined with another 
peptide through amide bonds, and is alternatively referred to 
as a polypeptide. Peptides comprise at least two amino acids, 
and are usually, but not exclusively, less than 50 amino acids 
in length. According to the invention, the peptide probes 
described herein may be partially or fully synthetic, and may, 
for example, comprise one or more of the following moieties: 
cyclized residues or peptides, multimers of peptides, labels, 
and/or other chemical moieties. The peptide probes of the 
invention described herein may interact with, but are not 
limited to, antibodies, or antigens such as specific proteins, 
nucleic acids, lipids, or polysaccharides. In some embodi 
ments, the peptide probes are generally specific for the target 
biomolecule to be detected. These peptides can be used as 
probes for antigens detection when the use of specific anti 
bodies is not necessary. 
According to the invention, the binding partner is labeled 
with a detectable marker directly or indirectly, so that the 
binding partner-biomolecule complex can be detected. 
According to the invention, a “detectable marker' is not 
restricted to a special type of detection marker, Such as bio 
chemical detection marker, but includes any residue known in 
the art which is suitable for detection. In some embodiments 
of the present invention, the binding partner defined above 
comprises a detectable marker that is a fluorescent marker, 
radioactive marker, or a redox-active marker. In some 
embodiments, the detectable marker includes, but is not lim 
ited to, a His-tag (detectable through its affinity to anti-His 
antibodies or with fluorescent probes bearing metal ions), 
glutathione transferase (GST) (detectable through its high 
affinity for glutathione), Flag-tag (detectable using antibodies 
against the flag sequence: N-DYKDDDDK-C), biotin (de 
tectable with anti-biotin antibodies or avidin/strepavidine 
tagged detection strategies such as horseradish peroxidase, 
alkaline phosphatase or fluorescent probes), Ha-tag (detect 
ably through its affinity for anti-HA antibody), and Myc-tag 
(detectable with an antibody against the Myc epitope). In 
some embodiments of the invention, the detectable marker is 
a redox molecule. The term “redox molecule.” “redox indi 
cator,” or “redox dye denotes a molecule which is capable of 













state. The change in redox state can be measured spectropho 
tometrically. Non-limiting examples of suitable redox mol 
ecules include redox indicators such as thionine, brilliant 
cresyl blue, methylene blue (3.7-bis(Dimethylamino) -phe 
nothiazin-5-ium chloride) and benzyl viologen. Other suit 
able redox molecules include, for example, alizarin brilliant 
blue, 2,6-dichlorophenolindophenol, gallocyanine, new 
methylene blue, N,N-dimethyl-disulphonated thionine, 
phenazine ethoSulphate, resorufin, Safrainine-O, phenothiazi 
none, toluidine blue-O, nile blue, ferrocene, anthraquinone, 
Ru(bpy), Os(bpy), Co(bpy), thidiaZuron (TDZ), 6-benzy 
laminopurine, and derivatives thereof. In one embodiment of 
the invention, the redox indicator is methylene blue. 
According to the invention, at least one target biomolecule 
in a specimen can be quantified by counting the signals of the 
detectable marker directly or indirectly. When the labeled 
marker is a redox molecule, dye, fluorophore or radioisotope, 
the presence of the biomolecule can be quantified directly by 
counting the signal of the marker. 
In Some embodiments, the binding partner is also function 
alized with a moiety capable of binding multivalent cations. 
In this embodiment, the moiety capable of binding a multi 
Valent cation includes chelating molecules. Here, the term 
“chelating molecule' or “chelating agent' includes any com 
pound that has the ability to bond to a metal ion through two 
or more atoms of the chelating agent to form a complex or a 
reaction product. The bonds may be covalent or ionic or a 
combination thereof. In some embodiments, the chelating 
agent comprises one or more amino acids. For example, in 
some embodiments, the chelating agent can comprise one or 
more histidine amino acids. In other embodiments of the 
invention, the chelating agent is a histidine (His) tag such as 
a hexahistidine moiety. In other embodiments of the inven 
tion, the chelating agent include compounds such as ethyl 
enediamine tetraacetic acid, nitrilo triacetic acid and sodium 
tripolyphosphate. Other Suitable chelating agents of the 
invention include, but are not limited to, chelating agents 
comprising nitrilotriacetic acid (NT A), 1,4,7-triazacy 
clononane (TACN), diethylene triamine pentaacetic acid 
(DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraace 
tic acid (DOTA), or imidazole moieties. 
In some embodiments, the SAM contains thiolated mol 
ecules that are adsorbed to a metal surface via a thiol-metal 
bond. In this embodiment, the metal Surface can include a 
gold surface. The sulfur/gold interaction is very stable and 
allows for the preparation of SAMs containing thiol func 
tional groups even in the presence of a variety of other Sub 
stituents. In some embodiments of the invention, the SAM 
can be formed on metal, metal alloy, or semiconductors Sur 
faces, including Pt, Cu, Pd, Ni, Ir, Ru, Ag, Hg, Zn, Ge. HgTe, 
AgS, AuAg, AuCu, CdS, FePt, GaAs, InP, PbS, PdAg., ZnSe, 
ZnS, CdSe, and stainless steel surfaces. Suitable surfaces are 
described in Chemical Reviews, 2005, 105(4) 1107, which is 
incorporated by reference herein in its entirety. 
In some embodiments, the SAM contains at least one sil 
anol functional group (or a precursor Such as an alkoxysilane 
that readily liberates a silanol upon exposure to moisture) that 
is capable of forming a covalent linkage to a siloxane or 
similar Surface. The SAM can be appended using silane group 
with a wide range of Substrates, including silicon-based mate 
rials (e.g., silicon wafers, silicon nanowires), diamond-based 
materials (e.g., boron-doped diamond Substrates), borosili 
cate and quartz. Substrates, transparent conducting electrode 
materials (e.g., indium tin oxide), and carbon-based materials 
(e.g., glassy carbon, carbon nanotubes). In some embodi 
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ments, the SAM contains at least one basic nitrogen in the 
form of an amine, imidazole, triazole, or the like, that can be 
absorbed to a metal surface. 
In some embodiments, a SAM is prepared by adsorbing the 
compound of Formula I or II onto a metal Surface. A surface 
bound SAM containing a terminal reactive group (Such as a 
chelating agent) can be used as platform onto which one can 
couple different peptide probes to the monolayer. 
In some embodiments, the monolayer can be formed by 
adsorbing a compound of Formula I or II, functionalized with 
a chelating agent (Such as imidazole), onto a gold disk elec 
trode, followed by Subsequent adsorption of a passivating 
diluent, such as 8-mercapto-1-octanol (C8-OH). The mixed 
monolayer is then exposed to metal ions for direct coordina 
tion with the surface-immobilized imidazole ligands. Various 
cations are known to coordinate with imidazole ligands. Such 
as metal ions Zinc (Zn(II)), cobalt (Co(II)), and nickel (Ni 
(II)). A histidine tagged methylene blue (His-MB) is then 
introduced to the metal-containing monolayer. Alternating 
current voltammetry (ACV) can then be used to characterize 
SAM by analysing the AC voltammetric peak consistent with 
the formal potential of the MB redox label. 
In some embodiments, the probe immobilization strategy 
described herein is not permanent and the attached probes can 
be effectively displaced by excess free ligands in the solution. 
The displacement or “regeneration' step provides a SAM that 
can be used multiple times for different sensing applications, 
Such as microfluidic-based sensing systems. 
The invention will be described in greater detail by way of 
specific examples. The following examples are offered for 
illustrative purposes, and are not intended to limit the inven 
tion in any manner. Those of skill in the art will readily 
recognize a variety of noncritical parameters which can be 
changed or modified to yield essentially the same results. 
EXAMPLES 
All reactions were carried out in flame dried glassware 
under an atmosphere of dry nitrogen. Solvents were used as 
purchased with the exception of THF and CHCl, which 
were distilled from Na/PhCO and CaFI, respectively. Thin 
layer chromatography (TLC) was performed on 0.25 mm 
hard-layer silica G plates; developed plates were visualized 
by UV lamp and/or by staining with vanillin, 1% aq. KMnO, 
(for unsaturated compounds), I, or phosphomolybdic acid. 
NMR spectra were obtained in CDC1s (using residual CHCl 
&=7.286 ppm) at 300, 400, 500, or 600 MHz for "H NMR 
spectra or at 75, 100, 125, or 150 MHz for 'C spectra, as 
indicated below. Infrared spectra were recorded as neat ATR 





















To a flame-dried round-bottomed flask equipped with a 
short air condenser was added HIO (0.41 equiv. 25.6 mmol. 
5.84 g) and methanol (36 mL). The mixture was stirred at rt 
and I (0.8 equiv., 50.2 mmol. 12.76 g) was added. The reac 
tion was stirred vigorously for 10 min, after which 1,2- 
dimethoxybenzene (1 equiv., 63 mmol, 8.7g, 8.0 mL) was 
added in one portion via Syringe. The reaction was then 
heated to 70° C. for 5h, producing a slurry comprising white 
Solid. The hot solution was poured into dilute aqueous 
NaSOs (100 mL) and cooled to rt. The solid was collected 
by filtration through a glass frit and washed with two 30 mL 
portions of cold methanol and dried in vacuo to afford 1,2- 
diiodo-4,5-dimethoxybenzene (21.07 g. 54 mmol. 86%) as a 
white solid. TLC R-0.49 (20% EtOAc/Hex); Melting point 
134.5-136.0° C. (134° C. lit.7). H NMR (600 MHz): & 7.25 






To a flame-dried round-bottomed flask was added 1,2- 
diiodo-4,5-dimethoxybenzene (1 equiv., 10 mmol. 3.90 g). 
The system was evacuated under nitrogen (3x), CHCl (70 
mL) was added, and the resulting solution was cooled to 0°C. 
BBr (2.5 equiv., 25 mmol. 25 mL of a 1.0 M solution in 
CHCl) was then added via syringe pump over 20 min. The 
reaction was stirred at 0°C. for 4h then quenched with HO 
(50 mL). The separated aqueous layer was then extracted with 
EtO (2x75 mL). The combined organic layers were dried 
with MgSO filtered through silica, and concentrated in 
vacuo to afford 1,2-dihydroxy-4,5-diiodobenzene (3.61 g, 
9.99 mmol, quantitative) as an off-white solid. TLCR, 0.50 
(50% EtOAc/Hex); Melting point 116.0-116.5°C.; H NMR 
(400 MHz, acetone-d): 88.48 (bs, 2H), 7.38 (s. 2H). 'C 
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4,5-diiodo-1,2-phenylene bis(trifluoromethanesulfonate) 
To a flame-dried round-bottomed flask was added 1,2- 
dihydroxy-4,5-diiodobenzene (1 equiv. 7.85 mmol. 2.84g), 
CHCl (55 mL), and pyridine (5 equiv. 39 mmol. 3.10 g, 
3.16 mL). The solution was cooled to 0°C. and Tf.O (2.2 
equiv., 17.3 mmol. 4.88 g, 2.91 mL) was added dropwise via 
syringe over 10 min. The reaction was stirred for 6 h while 
warming to ambient temperature, then cooled to 0°C. and 
quenched with HO (30 mL). The separated aqueous layer 
was extracted with CHCl (2x30 mL). The combined 
organic layers were dried with MgSO and filtered through a 
tall pad of silica. The pad was washed carefully with CHC1. 
to avoid the elution of impurities, and the filtrate was concen 
trated in vacuo to afford 4,5-diiodo-1,2-phenylene bis(trifluo 
romethanesulfonate) (4.90 g, 7.82 mmol, quantitative) as an 
off-white solid. The product is optionally purified by column 
chromatography (10% EtOAc/Hex). TLC R-0.60 (10% 
EtOAc/Hex); Melting point 46.5-47.7° C.; H NMR (400 
MHz): 87.91 (s. 2H); 'C NMR (100 MHz): 8 139.6, 133.4, 
118.5 (q, J-321.0 Hz), 108.0, FTIR: 1429, 1335, 1215, 
1125, 1105,868, 788, 745, 689 cm'. HRMS-ESI: calc. for 
CHFI NaOS (M+Na)": 648.7184. found: 648.7164. 
Step 4 
((pent-4-yn-1-yloxy)methyl)benzene 
To a flame-dried round-bottomed flask was added NaH (2 
equiv., 47.6 mmol. 1.9 g of a 60% dispersion in mineral oil). 
The solid was washed with hexanes (15 mL), THF (95 mL) 
was added and the suspension was cooled to 0°C. Pentynol (1 
equiv. 23.8 mmol. 2.0 g) was added drop wise in THF (5 mL), 
followed by drop wise addition of BnBr (0.92 equiv., 21.9 
mmol. 2.60 mL). The reaction was warmed to ambient tem 
perature over 16 h, quenched with saturated aqueous NHCl 
(25 mL), and diluted with water (20 mL). The organic layer 
was extracted with EtOAc (2x40 mL), washed with brine (40 
mL) and dried with NaSO. Product isolation was achieved 
by concentration in vacuo and purification by flash column 
chromatography to afford (pent-4-yn-1-yloxy)methyl)ben 
zene (3.60 g, 20.7 mmol, 94%). TLC R-0.41 (5% EtOAc/ 
Hex): 'HNMR (300 MHz): 8 7.29-7.44 (5H), 4.55 (s. 2H), 
3.61 (t, 2H, J=6.2 Hz), 2.36 (td, 2H, J=7.1, 2.6 Hz), 1.97 (t, 
1H, J=2.6 Hz), 1.81-193 (m, 2H). CNMR (75 MHz): 8 









A flame-dried 20 mL vial fitted with a screw-cap septa was 
charged with Pd(PPh3)C1 (0.06 equiv., 0.12 mmol. 84 mg), 
Cut (0.12 equiv., 0.24 mmol, 45.6 mg), and 4,5-diiodo-1,2- 
phenylene bis(trifluoromethanesulfonate) (1 equiv., 2 mmol. 













gen (3x), followed by the sequential addition of THF (4 mL), 
EtN (3 equiv., 6 mmol. 0.85 mL), and ((pent-4-yn-1-yloxy) 
methyl)benzene (2.3 equiv., 4.6 mmol. 802 mg) in THF (1 
mL). The reaction was stirred for 3 hat rt, filtered through a 
pad of silica and concentrated in vacuo. Purification by flash 
chromatography (step gradient from Hex to 10% EtOAc/ 
Hex) afforded 4,5-bis(5-(benzyloxy)pent-1-yn-1-yl)-1,2- 
phenylene bis(trifluoromethanesulfonate) (1.14 g, 1.59 
mmol, 79%). TLCR-0.27(10% EtOAc/Hex): 'HNMR (600 
MHz): 8 7.42 (s. 2H), 7.27-7.39 (10H), 4.56 (s, 4H), 3.65 (t, 
4H, J=6.0 Hz), 2.62 (t, 4H, J=7.1 Hz), 1.92-1.98 (m, 4H); 
'CNMR (150 MHz): & 138.8, 138.3, 128.4, 128.2, 127.59, 
127.56, 126.3, 121.7, 119.6, 117.5, 115.3, 98.1, 77.4, 73.0, 
68.5, 28.6, 16.5; FTIR: 2859, 2230, 1489, 1433, 1210, 1178, 
1135, 1080, 732 cm; HRMS-ESI: calc. for 
CHF.O.S.Na (M+Na)": 741.1027. found: 741.1039. 
Step 6 
pent-4-yn-1-ylbenzoate 
To a flame-dried round-bottomed flask was added pentynol 
(1 equiv. 24 mmol. 2.0 g) and CHCl (80 mL). The solution 
was cooled to 0°C. and BZC1 (1.2 equiv. 28 mmol. 3.3 mL) 
was added dropwise, followed by DMAP (0.1 equiv. 2.4 
mmol. 300 mg), and EtN (7 mL). The reaction was warmed 
to ambient temperature over 12 h, quenched with 2N HCl (10 
mL), extracted with EtOAc (2x40 mL), washed with brine (40 
mL) and dried over NaSO. The purified product was iso 
lated by concentrating in vacuo and purifying by flash chro 
matography (2.5% EtOAc/Hex) to afford pent-4-yn-1-ylben 
zoate (4.02g, 21.4 mmol. 89%). TLCR-0.57 (10% EtOAc/ 
Hex): 'HNMR (600 MHz): 88.03-8.07 (2H), 7.53-7.60 (1H), 
742-748 (2H), 4.44 (t, 2H, J=6.1 Hz), 2.40 (td, 2H, J–7.3, 2.7 
Hz), 1.98-2.05 (overlapping signals, 3H); 'CNMR (150 




A flame-dried 20 mL vial fitted with a screw-cap septa was 
charged with Pd(PPh)C1 (0.12 equiv., 0.18 mmol. 127mg), 
Cut (0.30 equiv., 0.45 mmol. 89.4 mg), and BuNI (3 equiv., 
4.5 mmol. 1.65 g). The vessel was evacuated and backfilled 
with nitrogen 3x, followed by the addition of 4.5-Bis(5-ben 
Zyloxypent-1-yn-1-yl)-1,2-phenylene bistrifluoromethane 
sulfonate in a 5:1 mixture of DMF/EtN (7 mL). The mixture 
was stirred for 5 min at rt, and 5-benzoyloxypentyne (4.1 
equiv., 6.1 mmol, 980 mg) was added in 1.5 ml of 5:1 DMF/ 
EtN. The reaction was placed in a 70° C. oil bath for 5.5 h, 
cooled to rt, and diluted with 1:1 CHC1/hexanes (40 mL). 
The solution was washed with HO (2x20 mL), 1N HCl (40 
mL), and brine (40 mL) and dried with MgSO. The product 
was isolated by concentrating the crude product in vacuo, and 
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purifying by flash chromatography (15% EtOAc/Hex) to 
afford (4,5-bis(5-(benzyloxy)pent-1-yn-1-yl)-1,2-phe 
nylene)bis(pent-4-yne-5,1-diyl) dibenzoate (930 mg, 1.17 
mmol, 79%). TLCR-0.39 (20% EtOAc/Hex): 'HNMR (600 
MHz): 8 8.04-8.10 (4H), 7.54-7.60 (2H), 742-747 (4H), 
7.39-7.41 (2H), 7.33-7.38 (8H), 727-7.31 (2H), 4.55 (s, 4H), 
4.53 (t, 4H, J=6.3 Hz), 3.66 (t, 4H, J=6.2 Hz), 2.70 (t, 4H, 
J–7.0 Hz), 2.60 (t, 4H, J–7.0 Hz), 2.11 (quint, 4H, 6.6 Hz), 
1.94 (quint, 4H, J=6.6 Hz). CNMR (150 MHz): & 166.5, 
138.5, 135.3, 133.0, 130.2, 129.6, 128.38, 128.36, 127.60, 
127.56, 125.3, 124.9, 95.0, 93.9, 79.6, 79.1, 73.0, 68.7, 63.7, 
28.9, 28.0, 16.7, 16.6; FTIR: 3675, 2988, 2972, 2901, 2229, 
1716, 1451, 1394, 1269, 1107, 1068, 1027, 900 cm; 





(pent-4-yne-5,1-diyl)dibenzoate (1 equiv., 1.11 mmol, 885 
mg) was dissolved in 10 mL of 1:1 Methanol/THF. The mix 
ture is equally partitioned among 5 straight-walled hydroge 
nation vials containing 20 mg of 10% Pd/C EtOAc. The vials 
were placed in a hydrogenation chamber and reacted at 40°C. 
and 30 psi H for 18 h. The individual reactions were com 
bined and filtered through a plug of Celite, concentrated in 
vacuo, and purified via flash chromatography (step gradient, 
30% EtOAc/Hex to 100% EtOAc) to afford 4,5-bis(5-hy 
droxypentyl)-1,2-phenylene)bis(pentane-5,1-diyl)diben 
zoate (253 mg,0.44 mmol, 40%). TLCR, 0.30 (60% EtOAc/ 
Hex) (-30% of the saturated dibenzoate derivative and ~10% 
of the saturated, monobenzoate derivative were also isolated. 
These compounds could be resubjected to the reaction con 
ditions to provide additional product): 'HNMR (600MHz): 8 
8.04-8.10 (4H), 7.54-7.61 (2H), 742-7.50 (4H), 6.94 (s. 2H), 
4.36 (t, 4H, J=6.7 Hz), 3.67 (t, 4H, J=6.6 Hz), 2.53-2.68 (8H), 
1.80-191 (6H), 1.53-1.72 (16H), 1.44-1.51 (4H); 'CNMR 
(150 MHz): 8166.7, 137.6, 137.3, 132.8, 130.4, 129.9, 129.5, 
128.3, 65.0., 62.7, 32.5, 32.21, 32.15, 31.2, 30.9, 28.6, 26.1, 
25.8: FTIR: 3776,2988,2972,2901, 1717, 1334, 1271, 1067, 
1057, 1028 cm; HRMS-ESI: calc. for C.H.O.Na 
(M+Na)": 653.3818. found: 653.3823. 
(4,5-bis(5-((methylsulfonyl)oxy)pentyl)-1,2-phenylene)bis 
(pentane-5,1-diyl)dibenzoate 
To a flamed-dried 20 mL vial fitted with a screw-cap septa 
was added (4,5-bis(5-hydroxypentyl)-1,2-phenylene)bis 
(pentane-5,1-diyl)dibenzoate (1 equiv., 0.34 mmol. 215 mg), 
CHCl (4 mL), and EtN (4 equiv., 1.36 mmol, 0.19 mL). 
The mixture was cooled to 0°C. and DMAP (0.1 equiv., 0.034 













of MsCl (3 equiv., 1.02 mmol, 0.08 mL). The reaction was 
warmed to ambient temperature over 14 hat which time the 
reaction was then quenched with sat. aq. NaHCO (10 mL). 
The organic and aqueous layers were separated and the aque 
ous layer was extracted with CHCl (3x10 mL). The com 
bined organic layers were washed with water (20 mL), dried 
with NaSO concentrated in vacuo, and purified by flash 
chromatography (45% EtOAc/Hex) to afford (4,5-bis(5- 
((methylsulfonyl)oxy)pentyl)-1,2-phenylene)bis(pentane-5, 
1-diyl)dibenzoate (294 mg. 0.37 mmol, 91%). TLC R-0.27 
(40% EtOAc/Hex): 'HNMR (600 MHz): 8 8.01-8.11 (4H), 
7.54-7.62 (2H), 7.46 (t, 4H, J–7.6), 6.92 (s. 2H), 4.35 (t, 4H, 
J=6.6 Hz), 4.26 (t, 4H, J=6.6 Hz), 3.02 (s, 6H), 2.60 (bt, 4H, 
J=8.0 Hz), 2.57 (bt, 4H, J=8.0), 1.77-188 (8H), 1.48-1.70 
(16H). CNMR (150 MHz): & 166.7, 137.6, 137.3, 132.9, 
130.5, 129.9, 129.5, 128.3, 70.1, 65.0, 37.4, 32.2, 32.1, 31.1, 
30.8, 29.1, 28.7, 26.2, 25.6; FTIR: 2937, 1714, 1352, 1272, 
1173, 1114, 1070,944, 908 cm; HRMS-ESI: calc. for 




To a flame-dried 8 mL vial fitted with screw-top cap was 
added 4,5-bis(5-((methylsulfonyl)oxy)pentyl)-1,2-phe 
nylene)bis(pentane-5,1-diyl)dibenzoate (1 equiv., 0.282 
mmol. 222 mg) and DMF (2.5 mL). The mixture was cooled 
to 0°C. and potassium thioacetate (3 equiv., 0.85 mmol, 97 
mg) was added. The reaction was warmed to ambient tem 
perature over 14 hat which time the reaction was diluted with 
Et2O (20 mL) and water (10 mL). The organic and aqueous 
layers were separated and the organic layer was washed with 
sat. aq. NaHCOs (3x10 mL), dried with NaSO. The crude 
product was then concentrated in vacuo, and purified by flash 
chromatography (10% EtOAc/Hex) to afford (4,5-bis(5- 
(acetylthio)pentyl)-1,2-phenylene)bis(pentane-5,1-diyl) 
dibenzoate (170 mg, 0.228 mmol, 81%); TLCR, 0.32 (15% 
EtOAc/Hex): 'HNMR (600 MHz): 8 8.07 (d, 4H, J–7.3 Hz), 
7.58 (t, 2H, J–74 Hz), 7.46 (t, 4H, J=7.8 Hz), 6.92 (s. 2H), 
4.36 (t, 4H, J=6.7 Hz), 2.90 (t, 4H, J=7.3 Hz), 2.60 (bt, 4H, 
J=7.9 Hz), 2.55 (bt, 4H, J=7.9 Hz), 2.35 (s, 6H), 1.80-1.89 
(8H), 1.54-1.70 (8H), 1.44-1.51 (4H); 'CNMR (150 MHz): 
& 195.9, 166.7, 137.5, 137.3, 132.8, 130.5, 129.9, 129.5, 
128.3, 65.0, 32.3, 32.2, 31.1, 30.9, 30.7, 29.5, 29.1, 28.7, 
26.3; FTIR: 3684,3675,2988,2972,2901, 1717, 1688, 1406, 
1394, 1383, 1230, 1057, 1028 cm; HRMS-ESI: calc. for 




A flame-dried 8 mL vial fitted with a screw-top cap was 
charged with (4,5-bis(5-(acetylthio)pentyl)-1,2-phenylene) 
US 9,079,835 B2 
27 
bis(pentane-5,1-diyl)dibenzoate (1 equiv., 0.193 mmol. 144 
mg) and THF (2.5 mL). i-BuAIH (DIBAl-H) (12 equiv. 2.3 
mmol. 1.55 mL of a nominally 1.5M solution intoluene) was 
added dropwise. The reaction was stirred at rt for 2.5h, cooled 
to 0°C., and quenched by the careful addition of 4 mL 2N 
HC1. The solution was diluted with water (10 mL), extracted 
with EtO (3x10 mL), washed with brine (10 mL), and dried 
over NaSO. The crude product was then concentrated in 
vacuo and purified via flash chromatography (50% EtOAc/ 
Hex) to afford 5.5'-(4,5-bis(5-mercaptopentyl)-1,2-phe 
nylene)bis(pentan-1-ol) (74 mg., 0.163 mmol. 84%). TLC 
R=0.19 (45% EtOAc/Hex): 'HNMR (600 MHz): 86.92 (s, 
2H), 3.68 (t, 4H, 6.6 Hz), 2.53-2.61 (12H), 1.56-1.72 (18H), 
1.45-1.53 (8H), 1.37 (t, 2H, J–7.9 Hz); CNMR (150MHz): 
& 137.6, 137.4, 129.9, 62.9, 33.9, 32.6, 32.3, 32.2, 31.2, 30.8, 
28.5, 25.9, 24.6; FTIR: 3353,2930, 2857, 2358, 2338, 1775, 
1460, 1143 cm; HRMS-ESI: calc. for C.H.O.S.Na 






To a flame-dried round-bottomed flask was added PPh. 
(1.1 equiv. 27.5 mmol. 7.21 g) and THF (65 mL). N-chloro 
succinimide (1.1 equiv. 27.5 mmol. 3.67 g) was dissolved in 
THF (50 mL) and added dropwise. The mixture was stirred 
for 5 min, and 9-decen-1-ol (1 equiv, 25 mmol. 3.91 g) was 
added dropwise in THF (30 mL). After 9 h, the volatile 
components of the reaction were evaporated and hexanes 
(100 mL) and HO (50 mL) were added. The liquid was 
decanted and the resulting Solid was washed with hexanes. 
The aqueous layer was collected and extracted with hexanes 
(2x50 mL). The combined organic layers were washed 
sequentially with bleach (30 mL) and brine (50 mL). The 
crude product was filtered through a pad of silica (which was 
washed with ~400 mL of hexanes) and concentration in vacuo 
to afford 10-chlorodecene (3.48 g. 20 mmol. 80%), which 
was deemed pure by NMR and used without further purifica 
tion. TLC R-0.87 (5% EtOAc/Hex): 'HNMR (400 MHz): 8 
5.84 (ddt, 1H, J=17.4, 10.3, 6.7 Hz), 5.02 (ddd, 1H, J=17.4, 
2.0, 3.6 Hz), 4.93-4.98 (m. 1H), 3.56 (t, 2H, J=6.5 Hz), 
2.02-2.12 (m, 2H), 1.74-1.84 (2H), 1.27-1.50 (10H): 
'CNMR (100 MHz): 8 139.2, 114.2, 45.2, 33.8, 32.7, 29.3, 





To a flame-dried round-bottomed flask, evacuated and 
backfilled with nitrogen (3x), was added 10-chlorodecene (1 













mmol. 36 mL), and CHCl (140 mL). Grubbs 2 catalyst 
(0.031 equiv, 0.48 mmol, 416 mg) was dissolved in CHCl 
(15 mL) and added to the reaction mixture in one portion. The 
reaction was stirred for 4 h, concentrated in vacuo, and puri 
fied by flash column chromatography (3% EtOAc/Hex) to 
afford (E)-methyl 1 1-chloroundec-2-enoate (3.14 g. 13.6 
mmol, 85%). TLC R-030 (5% EtOAc/Hex): 'HNMR (300 
MHz): 86.99 (dt, 1H, J=15.6, 7.0 Hz), 5.84 (dt, 1H, J=15.7, 
1.5 Hz), 3.75 (s, 3H), 3.55 (t, 2H, J=6.8 Hz), 2.22 (qd, 2H, 
J=7.3, 1.4 Hz), 1.72-1.85 (m, 2H), 1.26-1.55 (10H); 'CNMR 
(75 MHz): & 167.2, 149.6, 120.9, 51.4, 45.1, 32.6, 32.2, 29.2, 
29.0, 28.7, 27.9, 26.8; FTIR: 2928, 2856, 1722, 1657, 1435, 
1270,1195, 1174, 1041,979,720 cm; HRMS-ESI: calc. for 






To a flame-dried round-bottomed flask, evacuated and 
backfilled with nitrogen (3x) and equipped with a dropping 
funnel was added (E)-methyl 1 1-chloroundec-2-enoate (1 
equiv, 11.9 mmol, 2.77 g), THF (25 mL), MeOH (0.9 mL), 
and HMPA (25 mL). SmI (2.1 equiv, 25 mmol, 250 mL of a 
nominally 0.1 M solution in THF) was added rapidly in one 
portion via dropping funnel. The reaction was stirred for 0.5 
h, quenched by the dropwise addition of 2 NHCl (20 mL), 
and diluted with HO (100 mL) and EtO (100 mL). The 
layers were separated, and the aqueous layer was extracted 
with EtO (2x50 mL). The combined organic layers were 
washed with brine (2x50 mL), dried with MgSO, concen 
trated in vacuo, and purified by flash column chromatography 
(step-wise gradient 5% to 8% EtOAc/Hex) to afford Dim 
ethyl 3,4-bis(8-(chloro)octyl)hexanedioate (1.76 g) as a mix 
ture of stereoisomers and an unidentified impurity. TLC 
R-0.43 (10% EtOAc/Hex). 
The mixture can be used directly in the next reaction. 
Alternatively, the impurity can be removed by reacting the 
product (47 mg) with NaBH (3.8 mg) in THF (1 mL). After 
3.5h, the reaction was quenched with 3 mL HO, extracted 
with CHCl (3x5 mL), dried with NaSO concentrated in 
vacuo, and purified by flash column chromatography (10% 
EtOAc/Hex) to afford purified Dimethyl 3,4-bis(8-(chloro) 
octyl)hexanedioate (26 mg). TLC R-0.43 (10% EtOAc/ 
Hex): 'HNMR (300 MHz): 83.68 (s, 6H), 3.55 (t, 4H, J=6.8 
Hz), 1.91-2.35 (6H), 1.71-1.85 (4H), 1.13-1.50 (24H); 
'CNMR (75 MHz): & 173.94, 173.88, 51.54, 51.51, 45.14, 
37.4, 37.2, 36.2, 35.7, 32.6, 31.5, 30.7, 29.6, 29.3, 28.8, 27.4, 
27.3, 26.8; FTIR: 2927, 2855, 1735, 1435, 1251, 1191, 1165, 
1016, 722 cm; HRMS-ESI: calc. for C.H.ClNaO. 
(M+Na)": 489.2514. found: 489,2506. 










To a flame-dried 20 mL vial fitted with a screw-top septa 
cap was charged with pure dimethyl 3,4-bis(8-(chloro)octyl) 
hexanedioate (1 equiv, 0.46 mmol. 215 mg, mixture of Stere 
oisomers) and DMF (4 mL). KSAc (5 equiv, 2.3 mmol. 263 
mg) was added in one portion and the reaction was stirred for 
14 h at rt, diluted with EtO (25 mL), washed with sat. aq. 
NaHCO (2x10 mL), dried with NaSO, concentrated in 
vacuo, and purified by flash column chromatography (step 
wise gradient 5% to 10% EtOAc/Hex) to afford Dimethyl 
3,4-bis(8-(acetylthio)octyl)hexanedioate (215 mg. 85%). 
TLCR-0.32 (10% EtOAc/Hex): 'HNMR (300 MHz): 83.68 
(s, 6H), 2.87 (t, 4H, J–7.3 Hz), 1.92-1.40 (12H), 1.51-1.64 
(4H), 1.16-141 (24H); 'CNMR (75 MHz): & 1960, 174.0, 
173.9, 51.5,374,37.2,36.2,35.7, 31.5, 30.7, 30.6, 29.7, 29.5, 
29.4, 29.13, 29.06, 28.8, 27.4, 27.3; FTIR: 2926, 2854, 1736, 
1689, 1435, 1353, 1250, 1165, 1133, 1106, 1013,953 cm; 
HRMS-ESI: calc. for CH-NaOS (M+Na)": 569.2947. 
found: 569.2945. 
Stereochemical assignment was made by chiral HPLC 
analysis of the product mixture (ChiralPak IC, 90:10 Hex: 
iPrOH, 0.5 mL/min: UV detection was performed at 254 nm). 
The racemic (rac) Stereoisomer eluted as two peaks at 114 and 
119 min; the mesostereoisomer eluted at 142 min. The ratio 




To a flame-dried 20 mL vial fitted with a screw-top septa 
cap was charged with dimethyl 3,4-bis(8-(acetylthio)octyl) 
hexanedioate (1 equiv, 0.34 mmol, 187 mg, mixture of stere 
oisomers) and THF (4.5 mL). DIBAl-H (12 equiv. 4.1 mmol. 
2.7 mL of a nominally 1.5M solution in toluene) was added 
dropwise. The reaction was stirred for 3 hat rt, quenched by 
careful addition of 2 NHCl (5 mL), diluted with 10 mL sat. 
aq. NHCl (10 mL), and extracted with EtO(3x15 mL). The 
combined organic layers were washed with brine (1x15 mL), 
dried with NaSO, concentrated in vacuo, and purified by 
flash column chromatography (35% EtOAc/Hex) to afford 
rac-3,4-Bis(8-mercaptooctyl)hexane-1,6-diol (41 mg, 30%) 
and meso-3,4-Bis(8-mercaptooctyl)hexane-1,6-diol (49 mg, 
49%). TLC rac-R-0.57 (50% EtOAc/Hex), meso-R-0.38 
(50% EtOAc/Hex); rac: 'HNMR (400 MHz): & 3.60-3.79 
(4H), 2.54 (q, 4H, J=7.3 Hz), 1.14-1.68 (38H); 'CNMR (100 
MHz): 8 61.6, 35.8, 34.0, 33.7, 30.7, 30.0, 29.5, 29.1, 28.3, 
28.0, 24.6; FTIR: 3323, 2922, 2852, 1463, 1051, 722 cm; 













found: 429.2825; meso: 'HNMR (400 MHz): a 3.59-3.76 
(4H), 2.54 (q, 4H, J=7.3 Hz), 1.87 (bs, 2H), 1.08-1.68 (36H): 
CNMR (100 MHz): 8 61.9, 36.7, 34.0, 33.8, 30.7, 30.0, 
29.5, 29.1, 28.4, 28.0, 24.7: FTIR: 3329, 2922, 2852, 1463, 
1051, 721 cm; HRMS-ESI: calc. for CHNaOS, 




E H THPO(CH2)s 
9-Decyn-1-ol tetrahydropyranyl ether 
To a flame-dried round-bottomed flask was added 9-decyn 
1-ol (1 equiv. 32.4 mmol. 5.00 g), dihydropyran (1.5 equiv, 
48.6 mmol. 4.09 g, 4.5 mL), CHCl (50 mL), and PPTS (0.1 
equiv, 3.24 mmol. 800 mg). The reaction was stirred for 16h 
at rt and quenched with sat. aq. NaHCOs (40 mL). The layers 
were separated and the aqueous layer was extracted with 
CHCl (2x20 mL). The combined organic layers were 
washed with HO (30 mL), dried with NaSO, concentrated 
in vacuo, and purified by flash column chromatography (5% 
EtOAc/Hex) to afford 9-Decyn-1-ol tetrahydropyranyl ether 
(7.55g, 31.7 mmol, 98%). TLC R-030 (5% EtOAc/Hex): 
'HNMR (600 MHz): 8 4.55-4.62(1H), 3.83-3.91 (m, 1H), 
3.70-3.78 (m. 1H), 3.48-3.55 (m, 1H), 3.36-3.43 (m, 1H), 
2.19 (td, 2H, J, -7.1 Hz, J-2.6 Hz), 1.95 (t, 1H, J–2.6), 
1.80-1.89 (1H), 1.69-1.76 (1H), 1.50-1.63 (8H), 1.28-144 
(8H); 'CNMR (150 MHz): & 98.8, 84.7, 68.1, 67.6, 62.3, 




A flame-dried round-bottomed flask was charged with 
9-decyn-1-ol tetrahydropyranyl ether (1 equiv. 31.7 mmol. 
7.55g) and THF (40 mL), and cooled to -78° C. n-Bulli (1.1 
equiv. 34.9 mmol. 21.8 mL of a nominally 1.6M solution in 
hexanes) were added dropwise over 5 min. The reaction was 
stirred for 30 min at -78° C. and then added to a solution of 
methyl chloroformate (1.5 eq, 47.6 mmol. 4.50 g, 3.7 mL) in 
THF (20 mL) dropwise via cannula. The reaction was stirred 
for 30 minat -78°C., then warmed tort over 1 hand quenched 
dropwise with HO (40 mL). The layers were separated and 
the aqueous layer was extracted with EtO (2x25 mL). The 
combined organic layers were dried with NaSO, evaporated 
in vacuo, and purified by flash column chromatography (step 
gradient, 5% EtOAc/Hex to 10% EtOAc/Hex) to afford 
Methyl-11-(tetrahydro-2H-pyran-2-yl)oxy-undecynoate 
(8.50g, 28.7 mmol, 90%). TLC R-0.33 (10% EtOAc/Hex) 
HNMR (600 MHz): 8 4.55-4.61 (1H), 3.84-3.91 (m, 1H), 
3.70-3.78 (m plus ovlp. S. 4H), 3.47-3.54 (m. 1H), 3.39 (dt, 
1H, J,-9.6 Hz, J-6.7 Hz), 2.33 (t, 2H, J=7.1 Hz), 1.80-1.89 
(1H), 1.68-1.76 (1H), 1.50-1.63 (8H), 1.28-144 (8H): 
CNMR (150 MHz): & 1543, 98.9, 89.9, 72.9, 67.6, 62.3, 
52.5, 30.8, 29.7, 29.2, 28.9, 28.7, 27.5, 26.2, 25.5, 19.7, 18.6; 
FTIR: 2932, 2856, 2236, 1714, 1434, 1249, 1075, 1023,752 
cm'; HRMS-ESI: calc. for CH-NaO (M+Na)": 
3.19.1885. found: 319.1887. 








To a flame-dried round-bottomed flask equipped with two 
dropping funnels was added iPr-NH (2.5 equiv. 71.4 mmol. 
7.22 g, 10.0 mL) and THF (225 mL) and the solution was 
cooled to 0°C. nBuLi (2.5 equiv. 71.4 mmol. 44.6 mL of a 
nominally 1.6 M solution in hexanes) was added dropwise 
and the reaction was stirred for 30 min at 0°C. nBuSnH (2.3 
equiv, 65.6 mmol. 19.1 g, 17.7 mL) was added dropwise and 
the reaction was stirred for 30 min at 0°C. The reaction was 
cooled to -50° C. by the controlled addition of dry ice to 
acetone and CuCN (2.3 equiv, 65.6 mmol. 5.88 g) was added 
in one portion. The reaction was stirred for 45 min at -50° C. 
then cooled to -78° C. MeOH (1.70 mL) was added followed 
by the addition of methyl-11-(tetrahydro-2H-pyran-2-yl) 
oxy-undecynoate (1 equiv. 28.5 mmol, 8.46 g) in THF (85 
mL) in one portion. The reaction was stirred at -78°C. for 10 
min, then quenched with 170 mL of aq. NHCl/NH-OH (pH 
~8) and diluted with 150 mL EtO. The reaction was warmed 
to rt (orange color is discharged and Solution turns colorless), 
the layers were separated, and the aqueous layer extracted 
with EtO (3x120 mL). The combined organic layers were 
washed with aq. NHC1/NH-OH (pH-8) (100 mL), and brine 
(120 mL), dried with NaSO concentrated in vacuo, and 
purified by flash column chromatography (step gradient, Hex 
to 5% EtOAc/Hex) to afford (E)-methyl 11-((tetrahydro-2H 
pyran-2-yl)oxy)-3-(tributylstannyl)undec-2-enoate (15.1 g, 
25.5 mmol, 90%). TLC R-0.30 (5% EtOAc/Hex): 'HNMR 
(500 MHz): 8 5.86-6.03 (m, 1H), 4.56-4.62 (m, 1H), 3.85 
3.92 (m, 1H), 3.74 (dt, 1H, J, -9.6 Hz, J-6.9 Hz), 3.70 (s, 
3H), 3.47-3.54 (m, 1H), 3.39 (dt, 1H, J=9.6 Hz, J-6.7 Hz), 
2.78–2.97 (m,2H). 1.79-190 (1H), 1.69-1.77 (1H), 1.27-1.65 
(29H), 0.93-0.99 (5H), 0.91 (t, 9H, J=7.3 Hz); CNMR (125 
MHz): & 174.9, 164.6, 127.0, 98.8, 67.7, 62.3, 50.8, 35.3, 
30.8, 29.8, 29.77, 29.68, 29.5, 29.0, 27.4, 26.3, 25.5, 19.7, 
13.7, 10.0; FTIR: 2918, 2852, 1717, 1591, 1456, 1431, 1351, 
1189, 1162, 1136, 1121, 1077, 1022,867 cm; HRMS-ESI: 










To a flamed-dried round-bottomed flask was added (E)- 
methyl 11-((tetrahydro-2H-pyran-2-yl)oxy)-3-(tributylstan 
nyl)undec-2-enoate (1 equiv, 25.5 mmol. 15.0 g), DMF (30 













stirred for 3 hat rt, quenched with aq. NHCl/NH-OH (pH 
~8) (35 mL), and stirred for 2 h open to the air. The solution 
was diluted with H2O (50 mL) and EtO (50 mL). The layers 
are separated and the aqueous layer was extracted with Et2O 
(2x50 mL). The combined organic layers were washed with 
brine (75 mL), dried with MgSO, concentrated in vacuo, and 
purified by flash chromatography (step gradient, 10% EtOAc/ 
Hex to 15% EtOAc/Hex) to afford (2E,4E)-dimethyl 3,4-bis 
(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl)hexa-2,4-diene 
dioate (6.27g, 10.5 mmol, 83%). TLCR, 0.19 (10% EtOAc/ 
Hex): 'HNMR (500 MHz): 8 5.84 (bs, 2H), 4.55-461 (2H), 
3.83-3.92 (2H), 3.69-3.77 (s plus ovlp.m., 8H), 3.47-3.55 (m, 
2H), 3.38 (dt, 2H, J, -9.6 Hz, J-6.7 Hz), 2.72-2.84 (4H), 
1.78-1.89 (2H), 1.69-1.76 (2H), 1.50-1.63 (12H), 1.28-141 
(20H); 'CNMR (125 MHz): & 166.5, 1618, 117.6, 98.8, 
67.7, 62.3, 51.2, 30.8, 29.7, 29.6, 29.4, 29.3, 29.1, 28.7, 26.2, 
25.5, 19.7: FTIR: 2927, 2855, 1718, 1628, 1433, 1351, 1193, 
1163, 1136, 1078, 1023,986, 905, 868, 814 cm; HRMS 









A flame-dried round-bottomed flask was charged with Mg 
(15 equiv. 18.75 mmol. 456 mg) and equipped with a con 
denser. (2E,4E)-dimethyl 3,4-bis(8-((tetrahydro-2H-pyran 
2-yl)oxy)octyl)hexa-2,4-dienedioate (1 equiv. 744 mg, 1.25 
mmol) was added in MeOH (16 mL) and the reaction was 
stirred at rt. After ~30 min, the reaction began refluxing and 
was left to reflux for ~45 min upon which time the reaction 
was permitted to cool to it, quenched with sat. aq. NHCl (5 
mL), diluted with EtO (15 mL), and H2O (20 mL). The liquid 
was decanted into a separatory funnel and the remaining Solid 
was washed several times with EtO. The layers were sepa 
rated and the aqueous layer extracted with EtO (3x20 mL). 
The combined organic layers were washed with brine (30 
mL), dried with NaSO and concentrated in vacuo to afford 
Dimethyl 3,4-bis(8-((tetrahydro-2H-pyran-2-yl)oxy)octyl) 
hex-3-enedioate (565 mg crude mass, ~90% pure by 
HNMR, 0.95 mmol, 76%) as an inseparable 2:1 mixture of 
isomers which was used in the next reaction without further 
purification. TLCR-0.41 (20% EtOAc/Hex): HNMR (500 
MHz): & 4.61-4.56 (2H), 3.91-3.85 (2H), 3.77-3.70 (2H), 
3.67 (s, 4H), 3.66 (s. 2H), 3.54-3.47 (2H), 3.42-3.35 (2H), 
3.12 (s, 2.7H), 3.11 (s, 1.3H), 2.16-2.07 (4H), 1.90-1.80 (2H), 
1.76-1.69 (2H), 1.63-1.49 (12H), 1.40-1.24 (20H); 'CNMR 
(125 MHz): 8 172.4, 172.2, 130.7, 130.6, 98.9, 67.7, 62.4, 
51.8, 37.6, 37.2, 33.3, 32.9, 30.8, 29.8, 29.71, 29.68, 29.49, 
29.47, 28.3, 28.1, 26.2, 25.5, 19.7; FTIR: 2926, 2854, 1737, 
1434, 1295, 1200, 1156, 1136, 1119, 1078, 1022,988, 869, 
814 cm; HRMS-ESI: calc. for CHNaOs(M+Na)": 
619.418.6. found: 619.4174. 








A flamed-dried 20 mL vial fitted with screw-cap septa was 
charged with Dimethyl 3,4-bis(8-((tetrahydro-2H-pyran-2- 
yl)oxy)octyl)hex-3-enedioate (1 equiv, 0.855 mmol. 510 
mg), MeOH (10 mL) and PTSA (0.1 equiv, 0.086 mmol. 16.4 
mg). The reaction was stirred at rt for 14h, quenched with sat. 
aq. NaHCO, and diluted with CHCl (20 mL) and HO (10 
mL). The layers were separated and the aqueous layer was 
extracted with CHCl (2x20 mL). The combined organic 
layers were washed with HO (20 mL), dried with NaSO, 
concentrated in vacuo, and purified by flash chromatography 
(65% EtOAc/Hex) to afford Dimethyl 3,4-bis(8-hydroxyoc 
tyl)hex-3-enedioate (321 mg, 0.75 mmol, 88%) as an insepa 
rable 2:1 mixture of isomers. TLC R-0.19 (50% EtOAc/ 
Hex): 'HNMR (500 MHz): 83.61-3.70 (t plus two ovlp. s. 
10H, J=6.7 Hz), 3.13 (s, 2.7H), 3.11 (s, 1.3H), 2.07-2.18 (4H), 
1.57 (quint., 4H, J=7.8 Hz), 1.49 (bs, 2H), 1.26-1.40 (20H): 
'CNMR (125 MHz): & 1744, 1743, 130.7, 130.6, 62.99, 
51.8, 37.6, 37.2, 33.2, 32.82, 32.75, 29.6, 29.5, 29.44, 29.35, 
29.32, 28.3, 28.0, 25.71, 25.68: FTIR: 3375, 2926, 2854, 
1736, 1434, 1332,1242, 1192,1155, 1048 cm; HRMS-ESI: 







To a flamed-dried 20 mL vial fitted with a screw-cap septa 
was added Dimethyl 3,4-bis(8-hydroxyoctyl)hex-3-enedio 
ate (1 equiv, 0.642 mmol. 275 mg), CHCl (6 mL), and EtN 
(4 equiv, 2.57 mmol, 0.36 mL). The mixture was cooled to 0° 
C. and DMAP (0.1 equiv, 0.064 mmol, -8 mg) was added 
followed by the dropwise addition of MsCl (3 equiv, 1.93 
mmol, 0.15 mL). The reaction was allowed to come to ambi 
ent temperature over 14 h at which time the reaction was 
quenched with sat. aq. NaHCO (10 mL). The layers were 
separated and the aqueous layer was extracted with CH2Cl2 
(3x15 mL). The combined organic layers were washed with 
H2O (20 mL), dried with NaSO, concentrated in vacuo, and 
purified by flash column chromatography (45% EtOAc/Hex) 
to afford Dimethyl 3,4-bis(8-((methylsulfonyl)oxy)octyl) 
hex-3-enedioate (309 mg, 0.526 mmol. 82%) as an insepa 
rable 2:1 mixture of isomers. TLC R-0.24 (45% EtOAc/ 
Hex): 'HNMR (500 MHz): 8 420-4.25 (ovlp. ts, 4H), 3.68 
(s, 4H), 3.66 (s. 2H), 2.13 (s, 2.7H), 3.11 (s, 1.3H), 3.02 (s, 













'CNMR (125 MHz): & 172.3, 1722, 130.7, 130.6, 70.20, 
70.18, 51.8, 37.6, 37.4, 37.2, 33.2, 32.8, 31.6, 29.58, 29.55, 
29.33, 29.29, 29.1, 29.00, 28.97, 28.3, 28.0, 25.4; FTIR: 
2929, 2855, 1732, 1435, 1350, 1170,972, 935, 833, 721 
cm; HRMS-ESI: calc. for CHsNaOS (M+Na)": 







To a flamed-dried 20 mL vial fitted with a screw-cap septa 
was added Dimethyl 3,4-bis(8-((methylsulfonyl)oxy)octyl) 
hex-3-enedioate (1 equiv, 0.46 mmol. 269 mg) and DMF (4 
mL). The solution was cooled to 0°C. and KSAc (4 equiv, 
1.84 mmol. 210 mg) was added. The reaction was allowed to 
come to ambient temperature over 15h then diluted with EtO 
(25 mL) and H2O (10 mL). The layers were separated and the 
organic layer was washed with sat. aq. NaHCO, (3x10 mL), 
dried with NaSO, concentrated in vacuo, and purified by 
flash column chromatography (15% EtOAc/Hex) to afford 
Dimethyl 3,4-bis(8-(acetylthio)octyl)hex-3-enedioate (223 
mg, 0.405 mmol. 89%) as an inseparable 2:1 mixture of 
isomers (Note: partial separation could beachieved, however, 
both isomers were carried on to the next step). TLC R-0.43 
and 0.38 (20% EtOAc/Hex): 'HNMR (500 MHz): 83.68 (s, 
4H), 3.66 (s.2H), 3.12 (s.2.7H), 3.11 (1.3H), 2.84-2.90 (ovlp. 
t’s, 4H), 2.34 (s, 6H), 2.07-2.16 (4H), 1.52-1.61 (4H), 1.19 
1.40 (20H); CNMR (125 MHz): & 196.1, 1274, 172.2, 
130.7, 130.6, 51.8, 37.6, 37.2, 33.3, 32.8, 30.7, 29.7, 29.6, 
29.5, 29.38, 29.36, 29.13, 29.09, 29.07, 28.80, 28.78, 28.3, 
28.0, FTIR: 2924, 2850, 1733, 1691, 1431, 1338, 1190,1153, 
1134, 995, 951, 722 cm; HRMS-ESI: calc. for 
CHNaOS (M+Na)":567.2790, found: 567.2770. 
Step 9 
(Z)-3,4-bis(8-mercaptooctyl)hex-3-ene-1,6-diol 
To a flamed-dried 20 mL vial fitted with a screw-cap septa 
was added Dimethyl 3,4-bis(8-(acetylthio)octyl)hex-3-ene 
dioate (1 equiv, 0.36 mmol, 196 mg) and THF (4.5 mL). 
DIBAl-H (12 equiv. 4.3 mmol. 2.9 mL of a nominally 1.5 M 
solution in toluene) was added dropwise at rt. The reaction 
was stirred at rt for 2 hand quenched by the careful addition 
of 2N HCl (3 mL). The solution was transferred to a sepratory 
funnel and diluted with sat. aq. NHCl (15 mL) and EtO (15 
mL). The layers were separated and the aqueous layer 
extracted with EtO (2x15 mL). The combined organic layers 
were washed with brine (20 mL), dried with NaSO con 
centrated in vacuo, and purified by flash column chromatog 
raphy (40% EtOAc/Hex) to afford (Z)-3,4-bis(8-mercaptooc 
tyl)hex-3-ene-1,6-diol (82.8 mg, 0.205 mmol. 57%). TLC 
R-0.41 (50% EtOAc/Hex); Mp=67.4-68.2° C.; HNMR 
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(600 MHz): 83.64 (t, 4H, J–6.9 Hz), 2.54 (q, 4H, J–7.4 Hz), 
2.35 (t, 4H, J=7.0 Hz), 2.08-2.02 (4H), 1.68 (bs, 2H), 1.62 
(quint, 4H, J=7.4 Hz), 1.42-1.27 (22H); CNMR (150 
MHz): & 132.4, 61.3, 34.6, 34.0, 31.7, 29.7, 29.5, 29.2, 29.0, 
28.3, 24.6; FTIR:3402, 3349, 2923, 2850, 1465, 1348, 1028, 
721 cm; HRMS-ESI: calc. for CH-NaOS (M+Na)": 
427.2680. found: 427.2679. 
Example 4 




sulfuric acid (95%), sodium chloride, monosodium phos 
phate, disodium phosphate, nickel (II) chloride, imidazole, 
and ethylenediaminetetraacetic acid (EDTA) were purchased 
from Sigma-Aldrich (St. Louis, Mo.) and used as received 
without further purification. Diamond suspension (0.1 um) 
was purchased from Buehler (Lake Bluff, Ill.). Methylene 
blue histidine-tagged peptide: (His-MB) (His-His-His-His 
His-His-Lys-Methylene blue) was purchased from Xaia Cus 
tom Peptides (Göteborg, Sweden). 
All solutions were prepared with deionized water and puri 
fied through a Millipore Synergy system (18.2 MS2 cm, Mil 
lipore, Bedford, Mass.). The phosphate buffer saline (PBS) 
used in this study contained 8.02 mM NaHPO, 1.98 mM 
NaH2PO, and 100 mM NaCl (pH 7.4). 
Instrumentation 
Electrochemical measurements were performed at room 
temperature (22+1°C.) using a CHI 1040A Electrochemical 
Workstation (CH instruments, Austin, Tex.). Polycrystalline 
golddisk electrodes with a geometric area of 0.0314 cm were 
purchased from CH instruments (Austin, Tex.). The counter 
electrode (platinum wire electrode) and the reference elec 
trode (Ag/AgCl, 3M KCl) were also purchased from CH 
Instruments. 
Procedure 
Gold electrodes were primed by polishing with a 0.1 um 
diamond Suspension, rinsing with deionized water and Soni 
cating in a low power Sonicator for about five minutes to 
remove bound particulates. The electrodes were electro 
chemically cleaned by a series of oxidation and reduction 
cycles in 0.5 MHSO. The area of each electrode was deter 
mined by measuring the charge associated with a gold oxide 
stripping peak formed after the cleaning process in 0.05 M 
HSO4. After cleaning, the gold disk electrodes were rinsed 
with deionized water, dried with nitrogen and placed directly 
in a 100 uM solution of 1-(11-mercaptoundecyl)imidazole in 
ethanol for 10 minutes. Next, the electrodes were rinsed with 
ethanol and deionized water and placed in a 2 mM solution of 
8-mercapto-1-octanol for 3 hours. The electrodes were then 
rinsed with ethanol and deionized water. 
After formation of the self-assembled monolayer (SAM), 
electrodes containing the SAM were placed in a solution of 
NiCl, (100 mM) in PBS supplemented with EDTA (1 mM) 
for 30 minutes. The electrodes were then rinsed with deion 
ized water and histidine-tagged methylene blue (His-MB) 
(10-150 uL of 5uM solution in PBS) was dropcasted onto the 
electrodes for 1 hour. The electrodes were then rinsed thor 
oughly by washing with deionized water (1x5 mL), ethanol 
(1x2 mL), deionized water (1x5 mL), 1 M NaCl (1 M. 1x2 
mL), and deionized water (1x5 mL) 
FIG. 1 is a schematic, depicting the immobilization of 
His MB onto the imidazole-Ni SAM prepared in this 













dazole is immobilized on a gold electrode surface via a thiol 
gold bond. In the presence of a divalent cation, Such as NiCII), 
the imidazole chelating agent can efficiently capture His 
MB. 
The His-MB-bound electrodes were placed in an electro 
chemical cell containing PBS and analysed by alternating 
current voltammetry (ACV). AC voltammograms were 
recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz and 
with an AC amplitude of 25 mV. The electrodes were equili 
brated in PBS until a stable methylene blue peak current was 
obtained. In the displacement step, captured His-MB was 
displaced from the SAM by adding a high concentration of 
free imidazole (250 mM in PBS) to the electrochemical cell. 
The methylene blue peak current was then monitored for 
20-25 minutes. After displacement, the electrochemical cell 
was rinsed with deionized water and placed in a fresh aliquot 
of PBS for electrode re-equilibration. AC voltammograms 
were collected after the monolayer had equilibrated to 
achieve a stable methylene blue peak current. 
In the replacement step, His-MB was reintroduced to the 
SAM construct by incubating the electrodes in a new aliquot 
ofNiCl, (100 mM in PBS) and EDTA (1 mM) for 30 minutes. 
The electrodes were then rinsed with deionized water and 
Hist-MB (10-15 uL of a 5 uM solution in PBS) was drop 
casted onto the electrodes for 1 hour. The electrodes were then 
rinsed thoroughly by washing with deionized water (1x5 
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl 
(1 M, 1x2 mL), and deionized water (1x5 mL). The electrodes 
were subsequently placed in a fresh aliquot of PBS. AC vol 
tammograms were collected after the monolayer had equili 
brated to achieve a stable methylene blue peak current. 
FIG. 2A shows ACV data for His-MB immobilized on an 
imidazole-Ni SAM before and after displacement by free 
imidazole. FIG. 2B illustrates the displacement-replacement 
profile obtained during the experiment. As shown in FIG. 2B, 
the monolayer of the invention is very stable and can Sustain 
two distinct displacement and replacement cycles without 
Substantial changes in the capacitance current. 
Example 5 
Electrochemical Biosensor for Detecting Anti-Peanut 
Antibody (IgY) 
In this example, the imidazole-SAM prepared in Example 
4 was used in an electrochemical peptide-based sensor for 
direct detection of an anti-peanut allergen antibody (Igy) 
using a His-tagged peptide epitope from Arah2, a major pea 
nut allergen (His-Arah2-10-MB) (His-His-His-His-His 
His-Ser-Glu-Asp-Pro-Tyr-Ser-Pro-Ser-Pro-Tyr-Lys-Methyl 
ene blue, purchased from Xaia Custom Peptides, Göteborg, 
Sweden). The antibody target, IgY-APP-3, was purchased 
from Gallus Immunotech Inc. (Ontario, Canada). IgY-APP-3 
antibodies were obtained from hen eggs immunized with 
Arachis hypogaea protein extract. 
Gold electrodes containing the imidazole-SAM were 
placed in a solution of NiCl, (100 mM) in PBS supplemented 
with EDTA (1 mM) for 30 minutes. The electrodes were then 
rinsed with deionized water and histidine-tagged Arah2-10 
MB (10-15 uL of 5uM solution in PBS) was dropcasted onto 
the electrodes for 1 hour. The electrodes were then rinsed 
thoroughly by washing with deionized water (1x5 mL), etha 
nol (1x2 mL), deionized water (1x5 mL), 1 MNaCl (1 M, 1x2 
mL), and deionized water (1x5 mL) 
The His-Arah2-10-MB-bound electrodes were placed in 
an electrochemical cell containing PBS and analysed by alter 
nating current Voltammetry (ACV). AC Voltammograms 
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were recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz 
and with an AC amplitude of 25 mV. The electrodes were 
equilibrated in PBS until a stable methylene blue peak current 
was obtained. Antibodies against Arachis hypogaea protein 
extract (IgY-APP-3) were added consecutively in the follow 
ing concentrations: 0.5, 1, 10, 20, 30, 40, and 50 nM. 
FIG. 3 shows ACV data for His-Arah2-10-MB immobi 
lized on the imidazole-Ni SAM in the absence and presence 
of various concentrations of the anti-peanut IgY. As shown in 
FIG. 3, a large MB reduction peak is present, indicating 
Successful immobilization of the His-tagged peptide probe. 
The sensor responds to the target antibody in a concentration 
dependent manner, exhibiting an experimental detection limit 
of 500 mM. Control experiments further suggest that the 
binding is specific since negligible cross reactivity is 
observed when the sensor was interrogated with random IgY 
(data not shown). 
Example 6 
His-Tagged Methylene Blue Immobilized on 
Imidazole-Co and Imidazole-Zin Modified Sam 
In this example, 1 imidazole-Co and imidazole-Zn SAM 
constructs were prepared and analysed by ACV. Specifically, 
1-(11-mercaptoundecyl)imidazole was immobilized on a 
gold electrode as set forth in Example 4. After formation of 
the SAM, electrodes containing the SAM were placed in a 
solution of ZnCl2 (or CoCl) (100 mM) in PBS supplemented 
with EDTA (1 mM) for 1 hour. The electrodes were then 
rinsed with deionized water and histidine-tagged methylene 
blue (His-MB) (10-15 uL of 5 uM solution in PBS) was 
dropcasted onto the electrodes for 1 hour. The electrodes were 
then rinsed thoroughly by washing with deionized water (1x5 
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl 
(1 M. 1x2 mL), and deionized water (1x5 mL). 
The electrodes were placed in an electrochemical cell con 
taining PBS and analysed by ACV. AC voltammograms were 
recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz and 
with an AC amplitude of 25 mV. The electrodes were equili 
brated in PBS until a stable methylene blue peak current was 
obtained. In the displacement step, captured His-MB was 
displaced from the SAM by adding a high concentration of 
free imidazole (250 mM in PBS) to the electrochemical cell. 
The methylene blue peak current was then monitored for 
20-25 minutes. After displacement, the electrochemical cell 
was rinsed with deionized water and placed in a fresh aliquot 
of PBS for electrode re-equilibration. AC voltammograms 
were collected after the monolayer had equilibrated to 
achieve a stable methylene blue peak current. 
In the replacement step. His-MB was reintroduced to the 
SAM construct by incubating the electrodes in a new aliquot 
of ZnC1 (or CoC1,) (100 mM in PBS) and EDTA (1 mM) for 
1 hour. The electrodes were then rinsed with deionized water 
and His-MB (10-15 uL of a 5 uM solution in PBS) was 
dropcasted onto the electrodes for 1 hour. The electrodes were 
then rinsed thoroughly by washing with deionized water (1x5 
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl 
(1 M, 1x2 mL), and deionized water (1x5 mL). The electrodes 
were subsequently placed in a fresh aliquot of PBS. AC vol 
tammograms were collected after the monolayer had equili 
brated to achieve a stable methylene blue peak current. 
FIG. 4A shows ACV data for His-MB immobilized on an 
imidazole-Zn SAM before and after displacement by free 
imidazole. FIG. 4B illustrates ACV data for His-MB immo 














ment by free imidazole. As illustrated in this experiment, both 
Co(II) and Zn(II) are suitable for immobilization of the sur 
rogate probe, His-MB. 
Example 7 
Displacement of his-Tagged Methylene Blue from 
Sam Construct Using Histamine and Histidine 
In this example, the capacity of histidine and histamine to 
displace His-MB from the SAM constructs of the invention 
was tested. 1-(11-mercaptoundecyl)imidazole was immobi 
lized on a gold electrode as set forth in Example 4. After 
formation of the SAM, electrodes containing the SAM were 
placed in a solution of NiCl, (100 mM) in PBS supplemented 
with EDTA (1 mM) for 30 minutes. The electrodes were then 
rinsed with deionized water and histidine-tagged methylene 
blue (His-MB) (10-15 uL of 5 uM solution in PBS) was 
dropcasted onto the electrodes for 1 hour. The electrodes were 
then rinsed thoroughly by washing with deionized water (1x5 
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl 
(1 M. 1x2 mL), and deionized water (1x5 mL). 
The His-MB-bound electrodes were placed in an electro 
chemical cell containing PBS and analysed by alternating 
current voltammetry (ACV). AC voltammograms were 
recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz and 
with an AC amplitude of 25 mV. The electrodes were equili 
brated in PBS until a stable methylene blue peak current was 
obtained. In the displacement step, captured His-MB was 
displaced from the SAM by adding a high concentration of 
free L-histidine or histamine (250 mM in PBS) to the elec 
trochemical cell. The methylene blue peak current was then 
monitored for 20-25 minutes. After displacement, the elec 
trochemical cell was rinsed with deionized water and placed 
in a fresh aliquot of PBS for electrode re-equilibration. AC 
Voltammograms were collected after the monolayer had 
equilibrated to achieve a stable methylene blue peak current. 
In the replacement step. His-MB was reintroduced to the 
SAM construct by incubating the electrodes in a new aliquot 
of NiCl, (100 mM in PBS) and EDTA (1 mM) for 30 minutes. 
The electrodes were then rinsed with deionized water and 
His-MB (10-15 uL of a 5 uM solution in PBS) was drop 
casted onto the electrodes for 1 hour. The electrodes were then 
rinsed thoroughly by washing with deionized water (1x5 
mL), ethanol (1x2 mL), deionized water (1x5 mL), 1 MNaCl 
(1 M, 1x2 mL), and deionized water (1x5 mL). The electrodes 
were subsequently placed in a fresh aliquot of PBS. AC vol 
tammograms were collected after the monolayer had equili 
brated to achieve a stable methylene blue peak current. 
FIG. 5A shows ACV data for His-MB immobilized on an 
imidazole-Ni SAM before and after displacement by hista 
mine, and after replacement with His-MB. FIG. 4B shows 
ACV data for His-MB immobilized on an imidazole-Ni 
SAM before and after displacement by histidine, and after 
replacement with His-MB. As shown, the effectiveness of 
displacement of His-MB by histamine is similar to that 
observed with imidazole. Histidine is also capable of displac 
ing His-MB from the imidazole-Ni SAM. 
Example 8 
His-Tagged Methylene Blue Immobilized on a 
Nitrilotriacetic Acid SAM 
Gold electrodes were primed as set forth in Example 4. 
After cleaning, the gold disk electrodes were rinsed with 
deionized water, dried with nitrogen and placed directly in a 
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150 uM solution of 3:7 N. N.N-Bis(carboxymethyl)-L- 
lysine-12-mercaptododecanamine (C12-NTA): 8-mercapto 
1-octanol (C8-OH) solution in ethanol for 10 minutes. Next, 
the electrodes were rinsed with ethanol and deionized water 
and placed in a 2 mM solution of 8-mercapto-1-octanol over 
night. The electrodes were then rinsed with ethanol and 
deionized water. 
After formation of the self-assembled monolayer (SAM), 
electrodes containing the SAM were placed in a solution of 
NiCl, (100 mM) in PBS supplemented with EDTA (1 mM) 
for 30 minutes. The electrodes were then rinsed with deion 
ized water and histidine-tagged methylene blue (His-MB) 
(10-15 uL of 5 uM solution in PBS) was dropcasted onto the 
electrodes for 1 hour. The electrodes were then rinsed thor 
oughly by washing with deionized water (1x5 mL), ethanol 
(1x2 mL) and deionized water (1x5 mL). The His-MB 
bound electrodes were placed in an electrochemical cell con 
taining PBS and analysed by alternating current Voltammetry 
(ACV). AC voltammograms were recorded from -0.05 V to 
-0.45 V vs. Ag/AgCl at 10 Hz, and with an AC amplitude of 25 
mV. The electrodes were equilibrated in PBS until a stable 
methylene blue peak current was obtained. In the displace 
ment step, captured His-MB was displaced from the SAM by 
adding a high concentration of free imidazole (250 mM in 
PBS) to the electrochemical cell. The methylene blue peak 
current was then monitored for 20-25 minutes. After displace 
ment, the electrochemical cell was rinsed with deionized 
water and placed in a fresh aliquot of PBS for electrode 
re-equilibration. AC voltammograms were collected after the 
monolayer had equilibrated to achieve a stable methylene 
blue peak current. 
In the replacement step. His-MB was reintroduced to the 
SAM construct by incubating the electrodes in a new aliquot 
of NiCl, (100 mM in PBS) and EDTA (1 mM) for 30 minutes. 
The electrodes were then rinsed with deionized water and 
His-MB (10-15 uL of a 5 uM solution in PBS) was drop 
casted onto the electrodes for 1 hour. The electrodes were then 
rinsed thoroughly by washing with deionized water (1x5 
mL), ethanol (1x2 mL), deionized water (1x5 mL). The elec 
trodes were subsequently placed in a freshaliquot of PBS. AC 
Voltammograms were collected after the monolayer had 
equilibrated to achieve a stable methylene blue peak current. 
FIG. 6A shows ACV data for His-MB immobilized on an 
NTA-Ni SAM before and after displacement by free imida 
zole. As shown, His-MB can be successfully immobilized on 
a NTA-modified monolayer using Ni(II) as the metal ion. It 
was observed that NTA is a highly effective surface immobi 
lized ligand for probe capture. In the imidazole system, two 
imidazole head groups are desirable to achieve a stable metal 
ligand complex, whereas only one NTA ligand is needed for 
stabilized metal ligand complex formation. The NTA-Ni 
SAM can also withstand the displacement cycle without sig 
nificant loss of nickel metal ions, thus a “metal-replacement 
step” is not necessary. The captured His-MB probes can be 
easily displaced by excess amount of imidazole in the solu 
tion and the imidazole ligands can be effectively replaced by 
Hist-MB. 
Example 9 
His-Tagged Methylene Blue Immobilized on a 
Triazacyclononane SAM 
Gold electrodes were primed as set forth in Example 4. 
After cleaning, the gold disk electrodes were rinsed with 
deionized water, dried with nitrogen and placed directly in a 













0.17 mM Tris-(2-carboxymethyl)phosphine hydrochloride in 
deionized water for 1 hour) in ethanol for 10 minutes. Next, 
the electrodes were rinsed with ethanol and deionized water 
and placed in a 2 mM solution of 8-mercapto-1-octanol for 3 
hours. The electrodes were then rinsed with ethanol and 
deionized water. 
After formation of the self-assembled monolayer (SAM), 
electrodes containing the SAM were placed in a solution of 
ZnCl2 (100 mM) in PBS supplemented with EDTA (1 mM) 
for 30 minutes. The electrodes were then rinsed with deion 
ized water and histidine-tagged methylene blue (His-MB) 
(10-15 uL of 5 uM solution in PBS) was dropcasted onto the 
electrodes for 1 hour. The electrodes were then rinsed thor 
oughly by washing with deionized water (1x5 mL), ethanol 
(1x2 mL) and deionized water (1x5 mL). 
The His-MB-bound electrodes were placed in an electro 
chemical cell containing PBS and analysed by alternating 
current voltammetry (ACV). AC voltammograms were 
recorded from -0.05 V to -0.45 V vs. Ag/AgCl at 10 Hz and 
with an AC amplitude of 25 mV. The electrodes were equili 
brated in PBS until a stable methylene blue peak current was 
obtained. In the displacement step, captured His-MB was 
displaced from the SAM by adding a high concentration of 
free imidazole (250 mM in PBS) to the electrochemical cell. 
The methylene blue peak current was then monitored for 
20-25 minutes. After displacement, the electrochemical cell 
was rinsed with deionized water and placed in a fresh aliquot 
of PBS for electrode re-equilibration. AC voltammograms 
were collected after the monolayer had equilibrated to 
achieve a stable methylene blue peak current. 
FIG. 6B shows ACV data for His-MB immobilized on an 
TACN-Zn SAM. As shown, His-MB can be successfully 
immobilized on a TACN-modified monolayer using Zn(II) as 
the metal ion. 
Example 10 
Electrochemical Peptide-Based HIV Sensor 
Fabricated on an NTA-Ni SAM 
Materials 
HS-(CH)-EG-NTA (C11-EG3-NTA) was purchased 
from ProChimia Surfaces Sp. (Poland). Monocarboxymeth 
ylene blue NHS ester (NHS-MB) was purchased from emp 
Biotech GmbH (Berlin, Germany) and the dialysis bag (1000 
MW cut-off) was purchased from Spectrum Labs (Rancho 
Dominguez, Calif.). The protein probe and target (HIV-1 p24 
gag his and HIV-1 p24 antibody) was purchased from 
ProSpec Bio (Rehovot, Israel) and was reconstituted in PBS 
at a concentration of 76.9 uM and 6.66 uM respectively. 
6-mercapto-1-hexanol (C6-OH), Sulphuric acid (95%), 
hydrochloric acid, HEPES, trizma base, magnesium chloride, 
potassium chloride, calcium chloride, Sodium chloride, 
monosodium phosphate, disodium phosphate, nickel (II) 
chloride, imidazole, and ethylenediaminetetraacetic acid 
(EDTA) were used as received from Sigma-Aldrich (St. 
Louis, Mo.) without further purification. Diamond suspen 
sion, 0.1 um, was purchased from Buehler (Lake Bluff, Ill.). 
All the solutions were made with deionized water (DI 
HO), purified through a Millipore Synergy system (18.2 
MS2 cm, Millipore, Bedford, Mass.). The phosphate buffer 
saline (PBS) used in this study contained 8.02 mMNaHPO, 
1.98 mMNaH2PO, 100 mMNaCl, pH 7.4. The Phys2 buffer 
used in this study contained 20 mM Tris, 140 mM NaCl, 5 
mMKC1, 1 mM MgCl, and 1 mM CaCl pH 7.4. 
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Procedure 
HIV-1 P24 proteins (34.2 LM) were modified using a solu 
tion of NHS-MB (2.2 mM) in chilled HEPES (6.7 mM, pH 
9.5) by mixing the solution and allowing the solution to sit for 
90 minutes with a cold pack in the dark. The solution was then 
dialyzed for 4 hours in HEPES (20 mM, pH 9.5) and trans 
ferred to a 10 mM solution of HEPES (pH 7.5) overnight. 
Gold electrodes were polished and primed as set forth in 
Example 4. After cleaning, the gold disk electrodes were 
rinsed with deionized water, dried with nitrogen and placed 
directly in a 2 mM solution of 1:3 C11-EG3-NTA:C6-OH in 
ethanol for 24 hours at 4°C. Next, the electrodes were rinsed 
with ethanol and deionized water and dried with nitrogen gas. 
After formation of the SAM, electrodes containing the 
SAM were placed in a solution of NiCl2 (100 mM) in Tris 
HCL (10 mM, pH 8.0) for 30 minutes. The electrodes were 
then rinsed with deionized water and HIV-1 P24-MB (10-15 
uL of 7.3 uM solution in PBS) was dropcasted onto the 
electrodes for 1 hour. The electrodes were then rinsed thor 
oughly by washing with deionized water (1x5 mL), 5 
TWEEN 20 (1x2 mL) and deionized water (1x10 mL). The 
electrodes were then placed in an electrochemical cell con 
taining PhyS2 and analysed via alternating current Voltamme 
try (ACV). AC voltammograms were recorded from -0.1 V to 
-0.4V vs. Ag/AgCl at 10 Hz, and with an AC amplitude of 25 
mV. The electrodes were allowed to equilibrate in Phys2 until 
a stable MB peak current was obtained. The target, 50 nM 
anti-p24 antibodies were added to the Phys2 buffer and moni 
tored via ACV. 
FIG. 7 shows ACV data of the sensor prepared in this 
experiment in the absence and presence of anti-p-24 antibod 
ies. As illustrated in this experiment, His-tagged and MB 
modified HIV p24 antigent can be immobilized onto an NTA 
NiSAM of the invention. The MB signal is stable and a small 
reduction in the MB signal is evident upon addition of the 
target anti-p24 antibodies. 
Example 11 
His-Tagged Methylene Blue Immobilized on SAMs 
Fabricated with C11-Im, dS1-Im and dS2-Im 
Materials 
8-mercapto-1-octanol (C8-OH), sulphuric acid (95%), 
Sodium chloride, monosodium phosphate, disodium phos 
phate, nickel(II) chloride, trizma base, hydrochloric acid, and 
ethylenediaminetetraacetic acid (EDTA) were purchased 
from Sigma-Aldrich (St. Louis, Mo.) and used as received 
without further purification. Diamond suspension (0.1 um) 
was purchased from Buehler (Lake Bluff, Ill.). Methylene 
blue histidine-tagged peptide: (His-MB) (His-His-His-His 
His-His-Lys-Methylene blue) was purchased from Xaia Cus 
tom Peptides (Göteborg, Sweden). 
All solutions were prepared with deionized water and puri 
fied through a Millipore Synergy system (18.2 MS2 cm, Mil 
lipore, Bedford, Mass.). The phosphate buffer saline (PBS) 
used in this study contained 8.02 mM NaHPO, 1.98 mM 
NaH2PO, and 100 mM NaCl (pH 7.4). 
Instrumentation 
Electrochemical measurements were performed at room 
temperature (22+1°C.) using a CHI 1040A Electrochemical 
Workstation (CH instruments, Austin, Tex.). Polycrystalline 
gold disk electrodes with a geometric area of 0.0314 cm were 
purchased from CH instruments (Austin, Tex.). The counter 
electrode (platinum wire electrode) and the reference elec 
















Gold electrodes were primed by polishing with a 0.1 um 
diamond Suspension, rinsing with deionized water and Soni 
cating in a low power Sonicator for about five minutes to 
remove bound particulates. The electrodes were electro 
chemically cleaned by a series of oxidation and reduction 
cycles in 0.5 MHSO. The area of each electrode was deter 
mined by measuring the charge associated with a gold oxide 
stripping peak formed after the cleaning process in 0.05 M 
HSO. 
Before fabricating the monolayer, the dS-Im molecules 
were deprotected by allowing solutions containing the com 
pounds to incubate for 1 hour. Specifically, Solution A was 
prepared to contain either dS1-Im (1.5 mM) or dS2-Im (1.5 
mM) in solution with KOH (90mM in EtOH). Solution B was 
made after incubating Solution A for an hour by mixing 100 
uL of Solution A with 500 uL of 2 mM C8-OH in DI H.O. 
FIG. 8 shows the structures for compounds dS1-Im and dS2 
Im. 
After the cleaning process, the gold disk electrodes were 
rinsed with deionized water, dried with nitrogen and placed 
directly in solution B for 3 hours. Next, the electrodes were 
rinsed with ethanol and deionized water and placed in a 
solution of NiCl, (100 mM) in Tris-HCl (10 mM) for 30 
minutes. The electrodes were then rinsed with deionized 
water and histidine-tagged methylene blue (His-MB) (10-15 
uLof5uM solution in PBS, pH 8.0) for 1 hour. The electrodes 
were then rinsed thoroughly with PBS. 
The His-MB-bound electrodes were placed in an electro 
chemical cell containing PBS and analysed by alternating 
current voltammetry (ACV). AC voltammograms were 
recorded from -0.05 V to -0.5 V vs. Ag/AgCl at 10 Hz and 
with an AC amplitude of 25 mV. The electrodes were equili 
brated in PBS until a stable methylene blue peak current was 
obtained. In the displacement step, captured His-MB was 
displaced from the SAM by adding a high concentration of 
NiC1 (100 mM in 10 mM Tris-HCl) 250 mM in PBS) to the 
electrochemical cell. The methylene blue peak current was 
then monitored for 40 minutes. After displacement, the elec 
trochemical cell was rinsed with deionized water and placed 
in a fresh aliquot of PBS for electrode re-equilibration. AC 
Voltammograms were collected after the monolayer had 
equilibrated to achieve a stable methylene blue peak current. 
To replace probes that were removed in the displacement 
step, the electrodes were incubated in a new aliquot of His 
MB (5 uM in PBS pH 8.0) for 1 hour. The electrodes were 
then rinsed using PBS. The electrodes were subsequently 
placed in a freshaliquot of PBS and AC voltammograms were 
collected after the monolayer had equilibrated to achieve a 
stable methylene blue peak current. 
The ACV trace of the His-MB SAM fabricated using 
C11-Im, dS1-Im, and dS2-Im is shown in FIG. 9. FIG. 10A 
shows the ACV trace of the His-MB SAM fabricated dS1 
Im, before and after displacement with Ni(II), and after 
replacement with His-MB. FIG. 10B shows the ACV trace of 
the His-MB SAM fabricated dS2-Im, before and after dis 
placement with Ni(II), and after replacement with His-MB. 
As illustrated, the SAMs fabricated in this example can be 
used to immobilize histidine-modified peptide probes. The 
immobilized probes can be rapidly displaced by incubating 
the electrode in a Ni(II) solution. Replacement of the probes 
can be easily achieved by immersing the electrode in a new 
peptide probe solution. 
Various modifications of the invention, in addition to those 
described herein, will be apparent to those skilled in the art 
from the foregoing description. Such modifications are also 
intended to fall within the scope of the appended claims. Each 
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reference, including patents, patent applications, and publi 
cations, cited in the present application is incorporated herein 
by reference in its entirety. 
What is claimed is: 






R-V 2 Y-R 
wherein: 
R-R are each, independently, SR, OH, COR, heterocy 
clyl, heteroaryl, CN, N or halo: 
R is 0-2 R groups; 
X, Y, U, and V are each, independently, C-Calkyl; 
R is H. Coalkyl, C(O)H, CO (Coalkyl), SH, S(C. 
20alkyl); 
R, is Co-ohydroxyl, Coheterocycloalkyl, Cs-oaryl, 
Coheteroaryl, or NR'R''. 
R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, 
hydroxyl, halo, haloalkyl, haloalkoxy, cyano, nitro, 
azido, amino, alkylamino, dialkylamino, carboxy, car 
boxyalkyl ester, carboxy aryl ester, aminocarbonyl, 
alkylaminocarbonyl, dialkylaminocarbonyl, Sulfonyl, 
aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfo 
nyl, arylsulfonyl.arylsulfinyl, alkylsulfonyl, orarylsulfo 
nyl; and 
R and R' are each, independently selected from H, sub 
stituted or unsubstituted alkyl, 
or R and R' come together to form a 4-10-membered 
substituted or unsubstituted heterocyclic ring. 
2. The self-assembled monolayer of claim 1, wherein at 
least one of R. R. R. and R is SR 
3. The self-assembled monolayer of claim 1, wherein at 
least one of R. R. R. and R is S(Coalkyl). SC(O)(C. 
20alkyl), SH, or S(Coalkyl). 
4. The self-assembled monolayer of claim 1, wherein at 
least one of R. R. R. and R is SH or SC(O)(Coalkyl). 
5. The self-assembled monolayer of claim 1, wherein at 
least one of R. R. R. and R is SH. 
6. The self-assembled monolayer of claim 1, wherein at 
least one of R. R. R. and R is SC(O)(Coalkyl). 
7. The self-assembled monolayer of claim 1, wherein at 
least one of R. R. R. and R is SC(O)CH. 
8. The self-assembled monolayer of claim 1, wherein R 
and R2 are SR. 
9. The self-assembled monolayer of claim 1, wherein R 
and R are S(Coalkyl). SC(O)(Coalkyl), SH, or S(C- 
20alkyl). 
10. The self-assembled monolayer of claim 1, wherein R 
and R are SH or SC(O)(Coalkyl). 
11. The self-assembled monolayer of claim 1, wherein R 
and Rare SH. 
12. The self-assembled monolayer of claim 1, wherein R 
and R2 are SC(O)(Coalkyl). 
13. The self-assembled monolayer of claim 1, wherein R 
and Rare SC(O)CH. 
14. The self-assembled monolayer of claim 1, wherein at 
least one of R. R. R. and R is OH, C(O)R. N. heterocy 
clyl, or heteroaryl. 
15. The self-assembled monolayer of claim 1, wherein at 













16. The self-assembled monolayer of claim 1, wherein at 
least one of R. R. R. and R is CN. 
17. The self-assembled monolayer of claim 1, wherein R 
and R are OH, C(O)R. N. heterocyclyl, or heteroaryl. 
18. The self-assembled monolayer of claim 1, wherein R 
and Rare OH. 
19. The self-assembled monolayer of claim 1, wherein R 
and Ra are heterocyclyl or heteroaryl. 
20. The self-assembled monolayer of claim 1, wherein R 
and Ra are heterocyclyl. 
21. The self-assembled monolayer of claim 1, wherein R 
and Ra are 1.4.7-triazacyclononanyl. 
22. The self-assembled monolayer of claim 1, wherein R 
and Rare heteroaryl. 
23. The self-assembled monolayer of claim 1, wherein R 
and Rare pyridyl or imidazolyl. 
24. The self-assembled monolayer of claim 1, wherein R 
and Ra are pyridyl. 
25. The self-assembled monolayer of claim 1, wherein R 
and Ra are imidazolyl. 
26. The self-assembled monolayer of claim 1, wherein R 
and Ra are azido. 
27. The self-assembled monolayer of claim 1, wherein R 
and Rare CN. 
28. The self-assembled monolayer of claim 1, wherein R, 
is 0 Rc groups. 
29. The self-assembled monolayer of claim 1, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are OH: 
X, Y, U, and V are Calkyl; and 
R, is absent. 
30. The self-assembled monolayer of claim 1, wherein: 
R and R are SH or SCO (Coalkyl); 
R and R are OH or N: 
X, Y, U, and V are Ca1kyl; and 
R, is absent. 
31. The self-assembled monolayer of claim 1, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are N: 
X, Y, U, and V are Calkyl; and 
R, is absent. 
32. The self-assembled monolayer of claim 1, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are N: 
X, Y, U, and V are Csalkyl; and 
R, is absent. 
33. The self-assembled monolayer of claim 1, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Rare OH or N: 
X, Y, U, and V are Csalkyl; and 
R, is absent. 
34. The self-assembled monolayer of claim 1, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are imidazolyl: 
X, Y, U, and V are Calkyl; and 
R, is absent. 
35. The self-assembled monolayer of claim 1, wherein: 
R and R are SH or SCO (Coalkyl); 
R and Ra are imidazolyl; 
X, Y, U, and V are Calkyl; and 
R, is absent. 
36. The self-assembled monolayer of claim 1, wherein: 
R and R are SH or SCO Calkyl: 
R and Ra are imidazolyl; 
X and Y are each Calkyl: 
U and V are each Calkyl; and 
R, is absent. 

